| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 279 | 2025 | 685 | 39.490 |
Why?
|
| Movement Disorders | 105 | 2024 | 220 | 24.160 |
Why?
|
| Tourette Syndrome | 75 | 2024 | 155 | 18.460 |
Why?
|
| Botulinum Toxins, Type A | 65 | 2024 | 167 | 14.260 |
Why?
|
| Essential Tremor | 59 | 2025 | 89 | 14.140 |
Why?
|
| Botulinum Toxins | 68 | 2023 | 119 | 13.530 |
Why?
|
| Dystonia | 90 | 2024 | 172 | 12.710 |
Why?
|
| Tics | 32 | 2024 | 49 | 11.110 |
Why?
|
| Dystonic Disorders | 43 | 2024 | 85 | 10.560 |
Why?
|
| Torticollis | 50 | 2024 | 72 | 10.160 |
Why?
|
| Tremor | 68 | 2024 | 129 | 10.110 |
Why?
|
| Antiparkinson Agents | 53 | 2024 | 65 | 9.880 |
Why?
|
| Huntington Disease | 40 | 2024 | 143 | 8.830 |
Why?
|
| Deep Brain Stimulation | 48 | 2023 | 408 | 8.740 |
Why?
|
| Tic Disorders | 27 | 2024 | 78 | 8.540 |
Why?
|
| Parkinsonian Disorders | 30 | 2024 | 74 | 8.520 |
Why?
|
| Neuromuscular Agents | 37 | 2024 | 67 | 8.430 |
Why?
|
| Tetrabenazine | 32 | 2023 | 39 | 6.650 |
Why?
|
| Anti-Dyskinesia Agents | 30 | 2016 | 39 | 5.770 |
Why?
|
| Humans | 774 | 2025 | 124257 | 5.500 |
Why?
|
| Levodopa | 47 | 2024 | 91 | 5.440 |
Why?
|
| Dyskinesia, Drug-Induced | 31 | 2020 | 43 | 5.240 |
Why?
|
| Tardive Dyskinesia | 10 | 2023 | 12 | 4.990 |
Why?
|
| Blepharospasm | 28 | 2024 | 49 | 4.940 |
Why?
|
| Dopamine Agonists | 29 | 2024 | 79 | 4.800 |
Why?
|
| Chorea | 18 | 2021 | 39 | 4.480 |
Why?
|
| alpha-Synuclein | 20 | 2022 | 122 | 4.420 |
Why?
|
| Dopamine Antagonists | 16 | 2024 | 50 | 4.310 |
Why?
|
| Middle Aged | 347 | 2024 | 26608 | 4.260 |
Why?
|
| Dyskinesias | 11 | 2024 | 19 | 3.920 |
Why?
|
| Aged | 291 | 2024 | 19545 | 3.830 |
Why?
|
| Psychophysiologic Disorders | 10 | 2017 | 24 | 3.650 |
Why?
|
| Neuroprotective Agents | 29 | 2025 | 157 | 3.620 |
Why?
|
| Antipsychotic Agents | 26 | 2024 | 361 | 3.560 |
Why?
|
| Male | 422 | 2024 | 61033 | 3.450 |
Why?
|
| Brain | 44 | 2023 | 2981 | 3.250 |
Why?
|
| Gait Disorders, Neurologic | 15 | 2023 | 37 | 3.240 |
Why?
|
| Adult | 257 | 2024 | 29367 | 3.140 |
Why?
|
| Female | 397 | 2024 | 66312 | 3.110 |
Why?
|
| Neurotoxins | 12 | 2023 | 56 | 2.980 |
Why?
|
| Restless Legs Syndrome | 8 | 2024 | 16 | 2.840 |
Why?
|
| Globus Pallidus | 27 | 2013 | 64 | 2.640 |
Why?
|
| Supranuclear Palsy, Progressive | 14 | 2020 | 29 | 2.600 |
Why?
|
| Genetic Predisposition to Disease | 47 | 2022 | 3150 | 2.590 |
Why?
|
| Somatoform Disorders | 7 | 2019 | 45 | 2.550 |
Why?
|
| Stereotypic Movement Disorder | 4 | 2024 | 13 | 2.550 |
Why?
|
| Adrenergic Uptake Inhibitors | 10 | 2018 | 27 | 2.490 |
Why?
|
| Treatment Outcome | 107 | 2024 | 12286 | 2.460 |
Why?
|
| Hemifacial Spasm | 10 | 2016 | 17 | 2.440 |
Why?
|
| Conversion Disorder | 7 | 2019 | 9 | 2.410 |
Why?
|
| Vesicular Monoamine Transport Proteins | 7 | 2023 | 15 | 2.380 |
Why?
|
| Myoclonus | 10 | 2023 | 32 | 2.370 |
Why?
|
| Severity of Illness Index | 71 | 2024 | 2883 | 2.350 |
Why?
|
| Parkinson Disease, Secondary | 13 | 2024 | 20 | 2.330 |
Why?
|
| Trinucleotide Repeat Expansion | 10 | 2022 | 125 | 2.330 |
Why?
|
| Dopamine | 31 | 2020 | 286 | 2.290 |
Why?
|
| Nervous System Diseases | 11 | 2024 | 375 | 2.260 |
Why?
|
| Mutation | 41 | 2024 | 5816 | 2.240 |
Why?
|
| Subthalamic Nucleus | 12 | 2022 | 60 | 2.200 |
Why?
|
| Double-Blind Method | 50 | 2024 | 1630 | 2.120 |
Why?
|
| Hyperkinesis | 8 | 2016 | 24 | 2.060 |
Why?
|
| Neurologic Examination | 42 | 2022 | 194 | 2.060 |
Why?
|
| Age of Onset | 38 | 2024 | 586 | 2.050 |
Why?
|
| Nerve Tissue Proteins | 24 | 2013 | 1114 | 2.020 |
Why?
|
| Diagnosis, Differential | 37 | 2024 | 1881 | 1.950 |
Why?
|
| Tetrahydronaphthalenes | 8 | 2015 | 29 | 1.950 |
Why?
|
| Thiophenes | 8 | 2015 | 60 | 1.900 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 4 | 2020 | 25 | 1.900 |
Why?
|
| Basal Ganglia | 14 | 2023 | 55 | 1.860 |
Why?
|
| Neurodegenerative Diseases | 15 | 2025 | 249 | 1.810 |
Why?
|
| Aged, 80 and over | 87 | 2024 | 6467 | 1.690 |
Why?
|
| Movement | 15 | 2014 | 163 | 1.610 |
Why?
|
| Hand | 10 | 2019 | 98 | 1.610 |
Why?
|
| Adolescent | 103 | 2024 | 19253 | 1.560 |
Why?
|
| Huntingtin Protein | 6 | 2019 | 63 | 1.520 |
Why?
|
| Clinical Trials as Topic | 21 | 2023 | 1085 | 1.510 |
Why?
|
| Self-Injurious Behavior | 2 | 2023 | 61 | 1.500 |
Why?
|
| Acetylcholine Release Inhibitors | 5 | 2021 | 19 | 1.480 |
Why?
|
| Metoclopramide | 6 | 2015 | 10 | 1.480 |
Why?
|
| Neurons | 29 | 2021 | 1957 | 1.420 |
Why?
|
| Obsessive-Compulsive Disorder | 15 | 2022 | 776 | 1.380 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2023 | 257 | 1.370 |
Why?
|
| Posture | 18 | 2022 | 138 | 1.370 |
Why?
|
| Behavior Therapy | 5 | 2020 | 254 | 1.360 |
Why?
|
| Quality of Life | 18 | 2024 | 1899 | 1.360 |
Why?
|
| Leg | 4 | 2024 | 156 | 1.340 |
Why?
|
| Comorbidity | 18 | 2024 | 1530 | 1.310 |
Why?
|
| Spinocerebellar Ataxias | 5 | 2019 | 251 | 1.280 |
Why?
|
| Disease Progression | 25 | 2024 | 2044 | 1.240 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 11 | 2022 | 223 | 1.220 |
Why?
|
| Video Recording | 12 | 2024 | 182 | 1.210 |
Why?
|
| Golf | 2 | 2021 | 4 | 1.200 |
Why?
|
| Antibodies, Neutralizing | 4 | 2023 | 468 | 1.180 |
Why?
|
| Phenotype | 23 | 2021 | 4251 | 1.180 |
Why?
|
| Akathisia, Drug-Induced | 3 | 2018 | 11 | 1.160 |
Why?
|
| Muscle Contraction | 4 | 2021 | 188 | 1.150 |
Why?
|
| Cannabinoids | 2 | 2020 | 31 | 1.130 |
Why?
|
| Prodromal Symptoms | 2 | 2025 | 8 | 1.120 |
Why?
|
| Retrospective Studies | 45 | 2024 | 16294 | 1.120 |
Why?
|
| Dopamine Agents | 8 | 2020 | 28 | 1.090 |
Why?
|
| Clonidine | 2 | 2017 | 36 | 1.080 |
Why?
|
| Cerebrovascular Disorders | 5 | 2013 | 122 | 1.070 |
Why?
|
| Valine | 4 | 2020 | 113 | 1.060 |
Why?
|
| Nerve Degeneration | 14 | 2014 | 121 | 1.050 |
Why?
|
| Multiple System Atrophy | 10 | 2015 | 17 | 1.050 |
Why?
|
| Autonomic Nervous System Diseases | 8 | 2024 | 43 | 1.050 |
Why?
|
| Facial Muscles | 10 | 2018 | 33 | 1.050 |
Why?
|
| Immunotherapy | 4 | 2022 | 665 | 1.040 |
Why?
|
| Follow-Up Studies | 55 | 2023 | 5130 | 1.040 |
Why?
|
| Dose-Response Relationship, Drug | 34 | 2018 | 1689 | 1.020 |
Why?
|
| Pallidotomy | 6 | 2013 | 11 | 1.010 |
Why?
|
| Ubiquitin-Protein Ligases | 7 | 2019 | 357 | 1.010 |
Why?
|
| Animals | 75 | 2025 | 34047 | 0.980 |
Why?
|
| Indans | 6 | 2014 | 55 | 0.980 |
Why?
|
| Child | 70 | 2024 | 24363 | 0.970 |
Why?
|
| Genotype | 25 | 2022 | 2556 | 0.970 |
Why?
|
| Music | 4 | 2008 | 17 | 0.970 |
Why?
|
| Young Adult | 29 | 2024 | 9000 | 0.960 |
Why?
|
| Prospective Studies | 35 | 2024 | 6116 | 0.940 |
Why?
|
| Membrane Proteins | 11 | 2022 | 1531 | 0.930 |
Why?
|
| Clostridium botulinum | 4 | 2021 | 14 | 0.920 |
Why?
|
| Cognition Disorders | 12 | 2011 | 553 | 0.920 |
Why?
|
| Peripheral Nerve Injuries | 7 | 2011 | 37 | 0.900 |
Why?
|
| Autoimmune Diseases | 3 | 2017 | 251 | 0.890 |
Why?
|
| Muscle, Skeletal | 5 | 2021 | 942 | 0.880 |
Why?
|
| Functional Laterality | 16 | 2014 | 182 | 0.880 |
Why?
|
| Gait | 8 | 2023 | 83 | 0.880 |
Why?
|
| Mental Disorders | 9 | 2024 | 819 | 0.880 |
Why?
|
| Trinucleotide Repeats | 5 | 2017 | 109 | 0.870 |
Why?
|
| Speech Disorders | 5 | 2020 | 43 | 0.860 |
Why?
|
| Disease Management | 2 | 2020 | 519 | 0.860 |
Why?
|
| Spinal Cord Stimulation | 1 | 2023 | 10 | 0.850 |
Why?
|
| Injections, Intramuscular | 18 | 2024 | 195 | 0.840 |
Why?
|
| gamma-Aminobutyric Acid | 5 | 2015 | 174 | 0.820 |
Why?
|
| Lewy Body Disease | 3 | 2020 | 18 | 0.820 |
Why?
|
| Depression | 9 | 2018 | 1215 | 0.810 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 3 | 2017 | 5 | 0.810 |
Why?
|
| Drug Resistance | 11 | 2024 | 255 | 0.800 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 1017 | 0.790 |
Why?
|
| DNA Mutational Analysis | 20 | 2017 | 793 | 0.790 |
Why?
|
| Polymorphism, Genetic | 11 | 2010 | 811 | 0.790 |
Why?
|
| Toxins, Biological | 2 | 2020 | 69 | 0.780 |
Why?
|
| Substantia Nigra | 13 | 2015 | 34 | 0.770 |
Why?
|
| Autoimmunity | 2 | 2020 | 171 | 0.760 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2024 | 1104 | 0.750 |
Why?
|
| Transcription Factors | 13 | 2013 | 2582 | 0.740 |
Why?
|
| Carbidopa | 8 | 2022 | 18 | 0.740 |
Why?
|
| Blepharoptosis | 4 | 2017 | 67 | 0.740 |
Why?
|
| Foot | 3 | 2019 | 44 | 0.730 |
Why?
|
| Protein Kinases | 5 | 2019 | 332 | 0.730 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2018 | 504 | 0.730 |
Why?
|
| Gene Frequency | 17 | 2021 | 721 | 0.720 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 6 | 2015 | 32 | 0.720 |
Why?
|
| Injection Site Reaction | 1 | 2020 | 7 | 0.720 |
Why?
|
| Thiazoles | 9 | 2005 | 98 | 0.720 |
Why?
|
| Genetic Testing | 13 | 2021 | 997 | 0.710 |
Why?
|
| Serotonin Agents | 2 | 2020 | 14 | 0.710 |
Why?
|
| Surveys and Questionnaires | 20 | 2024 | 3688 | 0.700 |
Why?
|
| Voice Disorders | 4 | 2015 | 18 | 0.700 |
Why?
|
| Iron Metabolism Disorders | 6 | 2019 | 12 | 0.690 |
Why?
|
| Penetrance | 2 | 2020 | 102 | 0.690 |
Why?
|
| Postural Balance | 7 | 2021 | 79 | 0.690 |
Why?
|
| Time Factors | 36 | 2021 | 6279 | 0.690 |
Why?
|
| Neuroimmunomodulation | 1 | 2020 | 15 | 0.680 |
Why?
|
| Muscular Diseases | 3 | 2006 | 104 | 0.680 |
Why?
|
| Ventral Thalamic Nuclei | 6 | 2018 | 16 | 0.680 |
Why?
|
| Spasm | 7 | 2022 | 49 | 0.670 |
Why?
|
| Drug Administration Schedule | 17 | 2018 | 722 | 0.670 |
Why?
|
| Migraine Disorders | 3 | 2015 | 63 | 0.670 |
Why?
|
| Intellectual Disability | 3 | 2023 | 1054 | 0.660 |
Why?
|
| Cohort Studies | 26 | 2020 | 4779 | 0.650 |
Why?
|
| Pain | 7 | 2023 | 449 | 0.650 |
Why?
|
| Risk Factors | 37 | 2023 | 10243 | 0.650 |
Why?
|
| Heterozygote | 3 | 2019 | 671 | 0.640 |
Why?
|
| Skin Diseases | 1 | 2020 | 129 | 0.640 |
Why?
|
| Electric Stimulation Therapy | 8 | 2006 | 96 | 0.630 |
Why?
|
| Age Factors | 14 | 2019 | 2808 | 0.630 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2020 | 193 | 0.630 |
Why?
|
| Autophagy | 6 | 2019 | 389 | 0.620 |
Why?
|
| Ocular Motility Disorders | 4 | 2016 | 38 | 0.610 |
Why?
|
| H-Reflex | 3 | 2003 | 13 | 0.600 |
Why?
|
| Alleles | 16 | 2019 | 1614 | 0.600 |
Why?
|
| Neurosurgery | 3 | 2014 | 79 | 0.600 |
Why?
|
| Sialorrhea | 5 | 2012 | 16 | 0.600 |
Why?
|
| Musculoskeletal Diseases | 1 | 2019 | 57 | 0.600 |
Why?
|
| Anticonvulsants | 5 | 2009 | 375 | 0.600 |
Why?
|
| Atrophy | 8 | 2016 | 228 | 0.600 |
Why?
|
| Hypotension, Orthostatic | 4 | 2011 | 21 | 0.600 |
Why?
|
| Neuropsychological Tests | 21 | 2016 | 922 | 0.590 |
Why?
|
| Cognitive Dysfunction | 3 | 2021 | 227 | 0.590 |
Why?
|
| Vibration | 2 | 2016 | 31 | 0.590 |
Why?
|
| Thalamus | 9 | 2023 | 82 | 0.590 |
Why?
|
| Spine | 1 | 2019 | 143 | 0.590 |
Why?
|
| Dominance, Cerebral | 10 | 2009 | 56 | 0.590 |
Why?
|
| Sleep Bruxism | 1 | 2018 | 2 | 0.590 |
Why?
|
| Disability Evaluation | 12 | 2014 | 190 | 0.590 |
Why?
|
| Famous Persons | 2 | 2008 | 15 | 0.590 |
Why?
|
| Pedigree | 18 | 2022 | 1605 | 0.580 |
Why?
|
| DNA-Binding Proteins | 11 | 2008 | 2045 | 0.580 |
Why?
|
| Polymorphism, Single Nucleotide | 19 | 2021 | 2628 | 0.570 |
Why?
|
| Ageusia | 1 | 2017 | 2 | 0.570 |
Why?
|
| Ataxia | 5 | 2022 | 168 | 0.570 |
Why?
|
| Electromyography | 10 | 2014 | 162 | 0.560 |
Why?
|
| Caudate Nucleus | 4 | 2011 | 35 | 0.560 |
Why?
|
| Deception | 1 | 2017 | 11 | 0.560 |
Why?
|
| Olfaction Disorders | 1 | 2017 | 28 | 0.560 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2010 | 378 | 0.560 |
Why?
|
| Horner Syndrome | 1 | 2017 | 12 | 0.550 |
Why?
|
| Face | 7 | 2017 | 179 | 0.550 |
Why?
|
| Hepatolenticular Degeneration | 4 | 2019 | 34 | 0.550 |
Why?
|
| Tyrosine 3-Monooxygenase | 8 | 2012 | 53 | 0.540 |
Why?
|
| Consumer Health Information | 1 | 2017 | 25 | 0.540 |
Why?
|
| Proprioception | 1 | 2016 | 17 | 0.540 |
Why?
|
| Physical Stimulation | 1 | 2016 | 42 | 0.540 |
Why?
|
| Patient Safety | 1 | 2021 | 399 | 0.540 |
Why?
|
| Patient Satisfaction | 8 | 2018 | 472 | 0.540 |
Why?
|
| Antibodies | 6 | 2008 | 373 | 0.540 |
Why?
|
| Epitopes | 2 | 2018 | 432 | 0.530 |
Why?
|
| Cholinergic Antagonists | 6 | 2013 | 51 | 0.530 |
Why?
|
| Longitudinal Studies | 12 | 2016 | 1320 | 0.520 |
Why?
|
| Immunoglobulin G | 1 | 2019 | 776 | 0.520 |
Why?
|
| United States | 25 | 2023 | 10874 | 0.520 |
Why?
|
| Case-Control Studies | 25 | 2022 | 3267 | 0.520 |
Why?
|
| Motor Activity | 15 | 2017 | 509 | 0.520 |
Why?
|
| Telemedicine | 2 | 2021 | 428 | 0.510 |
Why?
|
| Prevalence | 9 | 2019 | 2445 | 0.510 |
Why?
|
| Stress, Psychological | 3 | 2007 | 541 | 0.510 |
Why?
|
| Substance-Related Disorders | 3 | 2018 | 453 | 0.510 |
Why?
|
| Pilot Projects | 8 | 2020 | 1369 | 0.510 |
Why?
|
| Magnetic Resonance Imaging | 21 | 2013 | 3551 | 0.510 |
Why?
|
| Injections | 7 | 2023 | 154 | 0.500 |
Why?
|
| Child, Preschool | 29 | 2023 | 13997 | 0.500 |
Why?
|
| Spinal Curvatures | 2 | 2018 | 4 | 0.500 |
Why?
|
| Frontotemporal Dementia | 1 | 2016 | 43 | 0.500 |
Why?
|
| Valproic Acid | 2 | 2014 | 162 | 0.500 |
Why?
|
| Compulsive Behavior | 2 | 2021 | 41 | 0.490 |
Why?
|
| Stereotaxic Techniques | 11 | 2007 | 70 | 0.490 |
Why?
|
| Electrodes, Implanted | 9 | 2014 | 169 | 0.490 |
Why?
|
| Heredodegenerative Disorders, Nervous System | 1 | 2015 | 11 | 0.490 |
Why?
|
| Sex Factors | 10 | 2019 | 1278 | 0.490 |
Why?
|
| Monitoring, Ambulatory | 2 | 2012 | 39 | 0.480 |
Why?
|
| Bruxism | 5 | 2008 | 5 | 0.480 |
Why?
|
| Ataxin-2 | 1 | 2015 | 8 | 0.480 |
Why?
|
| Lysosomal Storage Diseases | 2 | 2017 | 36 | 0.480 |
Why?
|
| Pergolide | 3 | 2005 | 5 | 0.480 |
Why?
|
| Stiff-Person Syndrome | 1 | 2014 | 5 | 0.470 |
Why?
|
| Ataxin-10 | 1 | 2015 | 28 | 0.470 |
Why?
|
| Videotape Recording | 9 | 2012 | 57 | 0.470 |
Why?
|
| Information Dissemination | 1 | 2017 | 186 | 0.470 |
Why?
|
| Corpus Striatum | 8 | 2023 | 90 | 0.470 |
Why?
|
| Jews | 1 | 2014 | 32 | 0.470 |
Why?
|
| Arm | 4 | 2012 | 81 | 0.470 |
Why?
|
| Genome-Wide Association Study | 11 | 2022 | 1682 | 0.470 |
Why?
|
| Catatonia | 1 | 2014 | 14 | 0.470 |
Why?
|
| Consensus | 6 | 2023 | 640 | 0.460 |
Why?
|
| Antimanic Agents | 1 | 2014 | 30 | 0.460 |
Why?
|
| Antiemetics | 1 | 2014 | 22 | 0.460 |
Why?
|
| Fluphenazine | 2 | 2013 | 5 | 0.460 |
Why?
|
| Point Mutation | 6 | 2009 | 346 | 0.460 |
Why?
|
| Ketorolac | 1 | 2014 | 17 | 0.460 |
Why?
|
| RNA-Binding Protein FUS | 1 | 2014 | 13 | 0.460 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 3 | 2012 | 30 | 0.460 |
Why?
|
| Neck Muscles | 6 | 2005 | 12 | 0.450 |
Why?
|
| Hyperhidrosis | 3 | 2012 | 9 | 0.450 |
Why?
|
| Internet | 1 | 2017 | 374 | 0.450 |
Why?
|
| Basal Ganglia Diseases | 7 | 1996 | 27 | 0.450 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2014 | 307 | 0.440 |
Why?
|
| Cytochrome P-450 CYP2D6 | 2 | 2016 | 31 | 0.440 |
Why?
|
| Selegiline | 5 | 2008 | 7 | 0.440 |
Why?
|
| Genetic Association Studies | 8 | 2023 | 778 | 0.440 |
Why?
|
| Administration, Cutaneous | 6 | 2014 | 66 | 0.440 |
Why?
|
| Peptides | 6 | 2017 | 794 | 0.440 |
Why?
|
| Iron | 5 | 2012 | 265 | 0.440 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2015 | 114 | 0.440 |
Why?
|
| Epilepsy | 1 | 2021 | 870 | 0.440 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 1211 | 0.440 |
Why?
|
| Vesicular Transport Proteins | 2 | 2022 | 120 | 0.440 |
Why?
|
| Calcinosis | 1 | 2015 | 177 | 0.430 |
Why?
|
| Registries | 4 | 2019 | 1421 | 0.430 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 151 | 0.430 |
Why?
|
| Reflex, Abnormal | 2 | 2004 | 16 | 0.430 |
Why?
|
| Shoulder Injuries | 1 | 2013 | 6 | 0.430 |
Why?
|
| GABA-A Receptor Agonists | 1 | 2013 | 6 | 0.430 |
Why?
|
| Sensitivity and Specificity | 11 | 2021 | 2041 | 0.420 |
Why?
|
| Multiple Sclerosis | 2 | 2014 | 329 | 0.420 |
Why?
|
| Evidence-Based Medicine | 3 | 2013 | 633 | 0.420 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 3 | 2010 | 70 | 0.420 |
Why?
|
| Blinking | 5 | 2021 | 27 | 0.420 |
Why?
|
| Biomarkers | 11 | 2024 | 3049 | 0.410 |
Why?
|
| F-Box Proteins | 1 | 2013 | 34 | 0.410 |
Why?
|
| Demyelinating Diseases | 1 | 2013 | 64 | 0.410 |
Why?
|
| Melanins | 1 | 2012 | 18 | 0.410 |
Why?
|
| Telephone | 3 | 2015 | 109 | 0.410 |
Why?
|
| Monophenol Monooxygenase | 1 | 2012 | 20 | 0.410 |
Why?
|
| Nuclear Proteins | 2 | 2011 | 1265 | 0.400 |
Why?
|
| Peptide Fragments | 7 | 2016 | 778 | 0.400 |
Why?
|
| Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 10 | 2019 | 19 | 0.400 |
Why?
|
| Neuroaxonal Dystrophies | 3 | 2023 | 13 | 0.400 |
Why?
|
| Neurosurgical Procedures | 5 | 2013 | 309 | 0.390 |
Why?
|
| Haplotypes | 13 | 2017 | 515 | 0.390 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2017 | 125 | 0.390 |
Why?
|
| Pyridines | 2 | 2013 | 229 | 0.390 |
Why?
|
| Activities of Daily Living | 12 | 2017 | 386 | 0.390 |
Why?
|
| Congenital Abnormalities | 1 | 2015 | 255 | 0.390 |
Why?
|
| Rotenone | 6 | 2015 | 16 | 0.390 |
Why?
|
| Benzothiazoles | 10 | 2015 | 30 | 0.390 |
Why?
|
| Meige Syndrome | 5 | 2005 | 9 | 0.390 |
Why?
|
| Dyspnea | 1 | 2012 | 152 | 0.370 |
Why?
|
| Fructose | 2 | 2009 | 62 | 0.370 |
Why?
|
| Nystagmus, Pathologic | 1 | 2011 | 22 | 0.370 |
Why?
|
| Encephalitis | 3 | 2012 | 109 | 0.370 |
Why?
|
| Acetylcysteine | 8 | 2012 | 72 | 0.370 |
Why?
|
| Apomorphine | 3 | 2001 | 3 | 0.370 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2011 | 18 | 0.360 |
Why?
|
| Sleep Wake Disorders | 5 | 2006 | 166 | 0.360 |
Why?
|
| Alcohols | 1 | 2010 | 18 | 0.360 |
Why?
|
| Indoles | 3 | 2015 | 179 | 0.360 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 11 | 2012 | 33 | 0.350 |
Why?
|
| Enzyme Inhibitors | 4 | 2010 | 577 | 0.350 |
Why?
|
| Genetic Variation | 11 | 2022 | 1493 | 0.350 |
Why?
|
| Glucosylceramidase | 3 | 2020 | 27 | 0.350 |
Why?
|
| Research Design | 5 | 2023 | 689 | 0.350 |
Why?
|
| Analysis of Variance | 9 | 2012 | 1010 | 0.350 |
Why?
|
| T-Lymphocytes | 5 | 2017 | 1708 | 0.350 |
Why?
|
| Receptors, Dopamine D3 | 3 | 2007 | 7 | 0.350 |
Why?
|
| Brain Chemistry | 3 | 2007 | 124 | 0.350 |
Why?
|
| Psychiatric Status Rating Scales | 8 | 2018 | 803 | 0.350 |
Why?
|
| Gastrointestinal Diseases | 2 | 2024 | 336 | 0.340 |
Why?
|
| Family Health | 4 | 2007 | 258 | 0.340 |
Why?
|
| Physical Therapy Modalities | 4 | 2019 | 50 | 0.340 |
Why?
|
| Epilepsies, Myoclonic | 2 | 2006 | 24 | 0.340 |
Why?
|
| Primary Dysautonomias | 1 | 2009 | 2 | 0.340 |
Why?
|
| MSX1 Transcription Factor | 1 | 2009 | 15 | 0.340 |
Why?
|
| Respiratory Tract Diseases | 1 | 2010 | 75 | 0.340 |
Why?
|
| Drug Tolerance | 2 | 2007 | 40 | 0.340 |
Why?
|
| Predictive Value of Tests | 10 | 2009 | 2143 | 0.330 |
Why?
|
| Apraxias | 2 | 2008 | 11 | 0.330 |
Why?
|
| Cranial Nerve Injuries | 1 | 2009 | 5 | 0.330 |
Why?
|
| Dopaminergic Neurons | 4 | 2014 | 48 | 0.330 |
Why?
|
| Wounds and Injuries | 5 | 2011 | 368 | 0.330 |
Why?
|
| Homeodomain Proteins | 2 | 2011 | 543 | 0.330 |
Why?
|
| Remote Consultation | 1 | 2009 | 24 | 0.330 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 854 | 0.320 |
Why?
|
| Sensation Disorders | 2 | 2013 | 19 | 0.320 |
Why?
|
| Propranolol | 2 | 2009 | 127 | 0.320 |
Why?
|
| Propylamines | 1 | 2009 | 8 | 0.320 |
Why?
|
| Medical Staff, Hospital | 1 | 2009 | 92 | 0.310 |
Why?
|
| Glasgow Outcome Scale | 1 | 2009 | 47 | 0.310 |
Why?
|
| Receptors, GABA-A | 2 | 2006 | 59 | 0.310 |
Why?
|
| Disorders of Excessive Somnolence | 2 | 2006 | 30 | 0.310 |
Why?
|
| Transcription Factor TFIID | 1 | 2008 | 13 | 0.310 |
Why?
|
| Stroke | 3 | 2024 | 977 | 0.310 |
Why?
|
| Postoperative Complications | 11 | 2009 | 3062 | 0.310 |
Why?
|
| TATA-Binding Protein Associated Factors | 1 | 2008 | 14 | 0.310 |
Why?
|
| Glutathione | 1 | 2010 | 193 | 0.310 |
Why?
|
| Molecular Chaperones | 3 | 2005 | 167 | 0.310 |
Why?
|
| Putamen | 5 | 2015 | 18 | 0.310 |
Why?
|
| Stuttering | 2 | 2015 | 5 | 0.310 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2011 | 680 | 0.300 |
Why?
|
| Shoulder Pain | 1 | 2008 | 14 | 0.300 |
Why?
|
| Receptors, Dopamine | 6 | 2016 | 40 | 0.300 |
Why?
|
| Reflex Sympathetic Dystrophy | 3 | 2005 | 4 | 0.300 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2020 | 70 | 0.300 |
Why?
|
| Amantadine | 2 | 2020 | 10 | 0.300 |
Why?
|
| Pedunculopontine Tegmental Nucleus | 1 | 2008 | 1 | 0.300 |
Why?
|
| Conflict of Interest | 1 | 2009 | 67 | 0.300 |
Why?
|
| Glucose | 2 | 2011 | 879 | 0.300 |
Why?
|
| Freezing Reaction, Cataleptic | 1 | 2008 | 5 | 0.300 |
Why?
|
| Neck | 5 | 2020 | 136 | 0.300 |
Why?
|
| Psychomotor Disorders | 1 | 2008 | 28 | 0.300 |
Why?
|
| Cacao | 1 | 2008 | 5 | 0.300 |
Why?
|
| Signal Transduction | 6 | 2017 | 4504 | 0.300 |
Why?
|
| Alcoholism | 1 | 2010 | 232 | 0.300 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2008 | 10 | 0.300 |
Why?
|
| Occupational Exposure | 2 | 2009 | 127 | 0.300 |
Why?
|
| Safety | 4 | 2013 | 219 | 0.300 |
Why?
|
| Occupational Diseases | 4 | 2009 | 75 | 0.300 |
Why?
|
| Cyclohexanecarboxylic Acids | 2 | 2015 | 18 | 0.300 |
Why?
|
| Anxiety | 6 | 2022 | 941 | 0.300 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2009 | 1284 | 0.300 |
Why?
|
| Stereotyped Behavior | 4 | 2015 | 37 | 0.290 |
Why?
|
| Hypoglycemic Agents | 2 | 2025 | 440 | 0.290 |
Why?
|
| Gambling | 1 | 2008 | 18 | 0.290 |
Why?
|
| Amines | 2 | 2015 | 36 | 0.290 |
Why?
|
| Head | 4 | 2020 | 103 | 0.290 |
Why?
|
| Alzheimer Disease | 10 | 2011 | 798 | 0.290 |
Why?
|
| Withholding Treatment | 1 | 2008 | 68 | 0.290 |
Why?
|
| Physician's Role | 1 | 2009 | 164 | 0.290 |
Why?
|
| Infant | 17 | 2021 | 12465 | 0.290 |
Why?
|
| Disclosure | 1 | 2009 | 148 | 0.290 |
Why?
|
| Syndrome | 5 | 2021 | 1119 | 0.290 |
Why?
|
| Gene Expression Regulation | 6 | 2019 | 2522 | 0.290 |
Why?
|
| Reflex, Babinski | 1 | 2007 | 1 | 0.290 |
Why?
|
| Genetic Loci | 2 | 2019 | 338 | 0.290 |
Why?
|
| Congresses as Topic | 1 | 2009 | 174 | 0.290 |
Why?
|
| Dementia | 4 | 2007 | 446 | 0.290 |
Why?
|
| Purines | 1 | 2008 | 114 | 0.290 |
Why?
|
| Alexia, Pure | 1 | 2007 | 3 | 0.290 |
Why?
|
| Malingering | 1 | 2007 | 20 | 0.280 |
Why?
|
| Trihexyphenidyl | 2 | 2020 | 2 | 0.280 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 2007 | 6 | 0.280 |
Why?
|
| Caffeine | 1 | 2008 | 70 | 0.280 |
Why?
|
| Melanoma | 2 | 2012 | 834 | 0.280 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2008 | 65 | 0.280 |
Why?
|
| Central Nervous System Stimulants | 2 | 2005 | 127 | 0.280 |
Why?
|
| Muscular Atrophy, Spinal | 2 | 2018 | 44 | 0.280 |
Why?
|
| Bell Palsy | 1 | 2007 | 5 | 0.280 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2011 | 94 | 0.280 |
Why?
|
| Eye Movements | 5 | 2022 | 69 | 0.280 |
Why?
|
| Chromosome Inversion | 1 | 2007 | 73 | 0.280 |
Why?
|
| Shoulder Dislocation | 1 | 2007 | 8 | 0.280 |
Why?
|
| Minocycline | 2 | 2004 | 36 | 0.280 |
Why?
|
| Eyelid Diseases | 4 | 1988 | 73 | 0.280 |
Why?
|
| Motor Skills | 6 | 2004 | 78 | 0.270 |
Why?
|
| Neostriatum | 2 | 2012 | 11 | 0.270 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2009 | 243 | 0.270 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 2004 | 72 | 0.270 |
Why?
|
| Cerebral Infarction | 3 | 1997 | 46 | 0.270 |
Why?
|
| Antibodies, Bacterial | 5 | 2011 | 388 | 0.270 |
Why?
|
| Epilepsia Partialis Continua | 1 | 2006 | 1 | 0.270 |
Why?
|
| International Cooperation | 4 | 2017 | 157 | 0.270 |
Why?
|
| Influenza, Human | 1 | 2013 | 657 | 0.270 |
Why?
|
| Electroconvulsive Therapy | 2 | 2020 | 67 | 0.270 |
Why?
|
| Running | 1 | 2006 | 35 | 0.270 |
Why?
|
| Epilepsy, Complex Partial | 1 | 2006 | 13 | 0.270 |
Why?
|
| Attitude to Health | 2 | 2006 | 255 | 0.270 |
Why?
|
| Drug Therapy, Combination | 6 | 2016 | 1162 | 0.270 |
Why?
|
| Joint Diseases | 1 | 2006 | 33 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2007 | 160 | 0.260 |
Why?
|
| Genetic Diseases, X-Linked | 2 | 2019 | 64 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2006 | 94 | 0.260 |
Why?
|
| Craniocerebral Trauma | 2 | 2012 | 139 | 0.260 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2014 | 555 | 0.260 |
Why?
|
| Acne Vulgaris | 1 | 2006 | 21 | 0.260 |
Why?
|
| Vagus Nerve | 1 | 2006 | 44 | 0.260 |
Why?
|
| Insanity Defense | 1 | 2006 | 3 | 0.260 |
Why?
|
| Drug Utilization Review | 1 | 2006 | 33 | 0.260 |
Why?
|
| Lysosomes | 1 | 2008 | 236 | 0.250 |
Why?
|
| Benzhydryl Compounds | 2 | 2005 | 66 | 0.250 |
Why?
|
| Growth Disorders | 1 | 2007 | 208 | 0.250 |
Why?
|
| Cerebellar Diseases | 2 | 2007 | 74 | 0.250 |
Why?
|
| Cholinergic Fibers | 1 | 2005 | 9 | 0.250 |
Why?
|
| Apoptosis | 7 | 2015 | 1782 | 0.250 |
Why?
|
| Gene-Environment Interaction | 2 | 2018 | 121 | 0.250 |
Why?
|
| Palate, Soft | 1 | 2005 | 16 | 0.250 |
Why?
|
| Welding | 1 | 2005 | 5 | 0.250 |
Why?
|
| Manganese Poisoning | 1 | 2005 | 3 | 0.250 |
Why?
|
| Foot Deformities | 1 | 2005 | 2 | 0.250 |
Why?
|
| Hand Deformities | 1 | 2005 | 4 | 0.250 |
Why?
|
| Amino Acid Sequence | 13 | 2016 | 2698 | 0.250 |
Why?
|
| Abdominal Muscles | 1 | 2005 | 27 | 0.250 |
Why?
|
| Pleura | 1 | 2005 | 20 | 0.250 |
Why?
|
| Catechol O-Methyltransferase Inhibitors | 3 | 2010 | 4 | 0.250 |
Why?
|
| Drug Combinations | 4 | 2022 | 268 | 0.250 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 3 | 2015 | 106 | 0.250 |
Why?
|
| Disease Models, Animal | 6 | 2014 | 4344 | 0.250 |
Why?
|
| Peripheral Nerves | 1 | 2005 | 85 | 0.250 |
Why?
|
| Pleural Diseases | 1 | 2005 | 27 | 0.250 |
Why?
|
| Hallucinations | 2 | 2002 | 26 | 0.240 |
Why?
|
| Autonomic Nervous System | 1 | 2005 | 44 | 0.240 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 2 | 2003 | 18 | 0.240 |
Why?
|
| Neural Conduction | 2 | 2003 | 92 | 0.240 |
Why?
|
| Reproducibility of Results | 10 | 2021 | 2861 | 0.240 |
Why?
|
| Neurocognitive Disorders | 4 | 1995 | 67 | 0.240 |
Why?
|
| Cerebral Cortex | 5 | 2006 | 451 | 0.240 |
Why?
|
| Drugs, Investigational | 1 | 2005 | 22 | 0.240 |
Why?
|
| Drug Industry | 1 | 2005 | 46 | 0.240 |
Why?
|
| Genetic Markers | 6 | 2011 | 604 | 0.240 |
Why?
|
| Manganese | 1 | 2005 | 48 | 0.240 |
Why?
|
| Antibodies, Blocking | 4 | 2011 | 61 | 0.240 |
Why?
|
| Terminology as Topic | 2 | 2018 | 222 | 0.240 |
Why?
|
| Wakefulness | 3 | 2022 | 97 | 0.240 |
Why?
|
| Hypokinesia | 2 | 2021 | 3 | 0.240 |
Why?
|
| Gastroparesis | 1 | 2006 | 67 | 0.240 |
Why?
|
| Piracetam | 1 | 2004 | 6 | 0.240 |
Why?
|
| Liver Diseases | 1 | 2009 | 365 | 0.240 |
Why?
|
| Deglutition Disorders | 5 | 2014 | 130 | 0.240 |
Why?
|
| Thalamic Nuclei | 4 | 2001 | 16 | 0.240 |
Why?
|
| Reaction Time | 4 | 2008 | 174 | 0.230 |
Why?
|
| Neuromuscular Diseases | 1 | 2005 | 56 | 0.230 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 87 | 0.230 |
Why?
|
| Protein Deglycase DJ-1 | 4 | 2019 | 12 | 0.230 |
Why?
|
| Immunodominant Epitopes | 2 | 2017 | 50 | 0.230 |
Why?
|
| Gene Dosage | 1 | 2006 | 439 | 0.230 |
Why?
|
| Nitrous Oxide | 1 | 2004 | 14 | 0.230 |
Why?
|
| Prognosis | 7 | 2014 | 4609 | 0.230 |
Why?
|
| Physical Examination | 3 | 2021 | 159 | 0.230 |
Why?
|
| Molecular Sequence Data | 14 | 2015 | 3873 | 0.230 |
Why?
|
| Motor Neuron Disease | 1 | 2004 | 15 | 0.230 |
Why?
|
| Pulmonary Fibrosis | 1 | 2005 | 106 | 0.220 |
Why?
|
| Pantothenate Kinase-Associated Neurodegeneration | 1 | 2004 | 2 | 0.220 |
Why?
|
| Carbon Monoxide | 1 | 2004 | 26 | 0.220 |
Why?
|
| Hemosiderosis | 1 | 2004 | 6 | 0.220 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2013 | 190 | 0.220 |
Why?
|
| Receptor, Notch3 | 1 | 2024 | 11 | 0.220 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2024 | 10 | 0.220 |
Why?
|
| CADASIL | 1 | 2024 | 7 | 0.220 |
Why?
|
| Binding Sites, Antibody | 4 | 2019 | 99 | 0.220 |
Why?
|
| Carrier Proteins | 6 | 2014 | 1022 | 0.220 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 822 | 0.220 |
Why?
|
| Depressive Disorder | 3 | 2017 | 450 | 0.220 |
Why?
|
| Enteric Nervous System | 2 | 2019 | 38 | 0.220 |
Why?
|
| Brain Injuries | 3 | 2008 | 765 | 0.220 |
Why?
|
| Muscle Rigidity | 2 | 2015 | 3 | 0.220 |
Why?
|
| Cerebellum | 3 | 2023 | 412 | 0.220 |
Why?
|
| Genetic Therapy | 4 | 2015 | 678 | 0.220 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 2 | 2014 | 30 | 0.220 |
Why?
|
| Biomechanical Phenomena | 1 | 2024 | 225 | 0.210 |
Why?
|
| Neurturin | 2 | 2015 | 3 | 0.210 |
Why?
|
| Membrane Transport Proteins | 4 | 2015 | 176 | 0.210 |
Why?
|
| Antibody Formation | 2 | 2023 | 265 | 0.210 |
Why?
|
| Neck Pain | 1 | 2023 | 19 | 0.210 |
Why?
|
| Motor Cortex | 2 | 2019 | 77 | 0.210 |
Why?
|
| Psychomotor Performance | 3 | 2008 | 181 | 0.210 |
Why?
|
| Kinesis | 1 | 2003 | 2 | 0.210 |
Why?
|
| Sirtuin 1 | 2 | 2015 | 42 | 0.210 |
Why?
|
| Genetic Heterogeneity | 1 | 2004 | 126 | 0.210 |
Why?
|
| Drug Administration Routes | 3 | 2016 | 32 | 0.210 |
Why?
|
| Cell Survival | 6 | 2015 | 806 | 0.210 |
Why?
|
| Anxiety Disorders | 2 | 2017 | 673 | 0.210 |
Why?
|
| tau Proteins | 4 | 2011 | 206 | 0.210 |
Why?
|
| History, 20th Century | 3 | 2018 | 383 | 0.210 |
Why?
|
| Tetracyclines | 1 | 2003 | 17 | 0.210 |
Why?
|
| Baclofen | 5 | 2018 | 39 | 0.210 |
Why?
|
| Pirenzepine | 1 | 2002 | 4 | 0.200 |
Why?
|
| Friedreich Ataxia | 1 | 2003 | 48 | 0.200 |
Why?
|
| Autoantibodies | 3 | 2017 | 434 | 0.200 |
Why?
|
| Emergencies | 1 | 2024 | 172 | 0.200 |
Why?
|
| Drug Delivery Systems | 2 | 2015 | 186 | 0.200 |
Why?
|
| Basal Ganglia Hemorrhage | 1 | 2002 | 1 | 0.200 |
Why?
|
| Accidents, Traffic | 2 | 2007 | 108 | 0.200 |
Why?
|
| Brain Damage, Chronic | 4 | 2007 | 30 | 0.200 |
Why?
|
| Antiphospholipid Syndrome | 2 | 2013 | 26 | 0.200 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2002 | 31 | 0.200 |
Why?
|
| Hypoxia | 1 | 2004 | 248 | 0.200 |
Why?
|
| Hearing Loss | 1 | 2003 | 134 | 0.200 |
Why?
|
| Blotting, Western | 5 | 2012 | 1103 | 0.200 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2014 | 96 | 0.200 |
Why?
|
| Amyloid beta-Peptides | 4 | 2011 | 211 | 0.200 |
Why?
|
| Ubiquinone | 2 | 2016 | 25 | 0.200 |
Why?
|
| Seizures | 3 | 2022 | 874 | 0.190 |
Why?
|
| Single-Blind Method | 6 | 2016 | 231 | 0.190 |
Why?
|
| North America | 5 | 2018 | 239 | 0.190 |
Why?
|
| Riluzole | 1 | 2002 | 21 | 0.190 |
Why?
|
| Muscle Weakness | 3 | 2014 | 83 | 0.190 |
Why?
|
| Verbal Behavior | 3 | 2009 | 47 | 0.190 |
Why?
|
| Serine | 3 | 2007 | 173 | 0.190 |
Why?
|
| Brain Diseases | 3 | 2012 | 298 | 0.190 |
Why?
|
| Psychomotor Agitation | 3 | 2012 | 54 | 0.190 |
Why?
|
| Retina | 2 | 2023 | 450 | 0.190 |
Why?
|
| Psychosurgery | 2 | 1999 | 27 | 0.190 |
Why?
|
| Glycine | 3 | 2007 | 168 | 0.190 |
Why?
|
| Fatigue | 2 | 2011 | 185 | 0.190 |
Why?
|
| Cross-Sectional Studies | 7 | 2022 | 3415 | 0.180 |
Why?
|
| Oncogene Proteins | 3 | 2011 | 136 | 0.180 |
Why?
|
| Muscles | 3 | 1991 | 289 | 0.180 |
Why?
|
| Radiosurgery | 2 | 2001 | 108 | 0.180 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2021 | 5 | 0.180 |
Why?
|
| Symptom Assessment | 1 | 2021 | 100 | 0.180 |
Why?
|
| Medical Marijuana | 1 | 2020 | 5 | 0.180 |
Why?
|
| Fragile X Syndrome | 1 | 2022 | 150 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 9 | 2009 | 1585 | 0.170 |
Why?
|
| Proteins | 2 | 2005 | 1036 | 0.170 |
Why?
|
| RNA-Binding Proteins | 1 | 2004 | 573 | 0.170 |
Why?
|
| Serotonin | 3 | 2018 | 229 | 0.170 |
Why?
|
| Databases, Genetic | 2 | 2019 | 472 | 0.170 |
Why?
|
| Accidental Falls | 2 | 2016 | 71 | 0.170 |
Why?
|
| Biological Assay | 3 | 2008 | 102 | 0.170 |
Why?
|
| Acetates | 1 | 2000 | 72 | 0.170 |
Why?
|
| Membrane Glycoproteins | 4 | 2010 | 409 | 0.170 |
Why?
|
| Cathepsin B | 1 | 2020 | 10 | 0.170 |
Why?
|
| Mandibular Diseases | 1 | 1999 | 9 | 0.170 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 69 | 0.170 |
Why?
|
| Internationality | 1 | 2020 | 131 | 0.170 |
Why?
|
| Adolescent Behavior | 1 | 2021 | 168 | 0.170 |
Why?
|
| Proteasome Endopeptidase Complex | 5 | 2012 | 263 | 0.170 |
Why?
|
| Muscarinic Antagonists | 1 | 2020 | 38 | 0.170 |
Why?
|
| HLA-DQ beta-Chains | 2 | 2017 | 15 | 0.170 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2000 | 94 | 0.160 |
Why?
|
| Rest | 2 | 2015 | 57 | 0.160 |
Why?
|
| Craniomandibular Disorders | 1 | 1999 | 1 | 0.160 |
Why?
|
| Cell Line, Tumor | 8 | 2015 | 3331 | 0.160 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2019 | 7 | 0.160 |
Why?
|
| Liability, Legal | 2 | 2009 | 44 | 0.160 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 117 | 0.160 |
Why?
|
| Iron Chelating Agents | 2 | 2010 | 14 | 0.160 |
Why?
|
| Neural Pathways | 4 | 2007 | 266 | 0.160 |
Why?
|
| Immune System | 1 | 2020 | 90 | 0.160 |
Why?
|
| Autistic Disorder | 3 | 2005 | 343 | 0.160 |
Why?
|
| Benzodiazepines | 2 | 2014 | 98 | 0.160 |
Why?
|
| Cells, Cultured | 8 | 2017 | 3038 | 0.160 |
Why?
|
| Radiopharmaceuticals | 2 | 2015 | 161 | 0.160 |
Why?
|
| Serogroup | 1 | 2019 | 58 | 0.160 |
Why?
|
| Brain Stem | 2 | 2007 | 115 | 0.160 |
Why?
|
| Protein Aggregates | 1 | 2019 | 28 | 0.160 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2019 | 62 | 0.160 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 157 | 0.160 |
Why?
|
| Mitochondrial Proteins | 2 | 2019 | 229 | 0.160 |
Why?
|
| Expert Testimony | 3 | 2015 | 37 | 0.160 |
Why?
|
| Mice | 26 | 2017 | 17626 | 0.160 |
Why?
|
| Handwriting | 3 | 1993 | 8 | 0.160 |
Why?
|
| Electric Stimulation | 5 | 2004 | 321 | 0.150 |
Why?
|
| Sleep | 1 | 2002 | 339 | 0.150 |
Why?
|
| Central Nervous System Depressants | 1 | 2018 | 23 | 0.150 |
Why?
|
| DiGeorge Syndrome | 1 | 2019 | 79 | 0.150 |
Why?
|
| Diagnostic Imaging | 2 | 2011 | 276 | 0.150 |
Why?
|
| Sequence Analysis, DNA | 4 | 2016 | 1748 | 0.150 |
Why?
|
| Chronic Disease | 4 | 2012 | 1179 | 0.150 |
Why?
|
| Facial Injuries | 1 | 1998 | 22 | 0.150 |
Why?
|
| Recovery of Function | 1 | 2021 | 440 | 0.150 |
Why?
|
| Beta Rhythm | 1 | 2018 | 22 | 0.150 |
Why?
|
| Vision Disorders | 1 | 2020 | 211 | 0.150 |
Why?
|
| Self Mutilation | 2 | 1988 | 5 | 0.150 |
Why?
|
| Lesch-Nyhan Syndrome | 2 | 1988 | 11 | 0.150 |
Why?
|
| Benzazepines | 1 | 2018 | 65 | 0.150 |
Why?
|
| Cross-Over Studies | 3 | 2018 | 311 | 0.150 |
Why?
|
| Forensic Medicine | 1 | 1998 | 12 | 0.150 |
Why?
|
| Austria | 2 | 2008 | 19 | 0.150 |
Why?
|
| Behavioral Symptoms | 2 | 2008 | 25 | 0.150 |
Why?
|
| Founder Effect | 2 | 2009 | 32 | 0.150 |
Why?
|
| Headache | 2 | 2016 | 107 | 0.150 |
Why?
|
| Ferritins | 4 | 2012 | 97 | 0.150 |
Why?
|
| Heredity | 1 | 2017 | 15 | 0.150 |
Why?
|
| Cathepsin D | 1 | 2017 | 16 | 0.150 |
Why?
|
| Organic Anion Transporters | 1 | 2017 | 16 | 0.150 |
Why?
|
| Acid Ceramidase | 1 | 2017 | 5 | 0.150 |
Why?
|
| History, 18th Century | 2 | 2008 | 70 | 0.150 |
Why?
|
| Memory Disorders | 3 | 2009 | 236 | 0.150 |
Why?
|
| Drug Approval | 1 | 2018 | 42 | 0.150 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2016 | 72 | 0.140 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2017 | 41 | 0.140 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2017 | 17 | 0.140 |
Why?
|
| Drug Substitution | 1 | 2017 | 19 | 0.140 |
Why?
|
| HLA-DRB1 Chains | 1 | 2017 | 38 | 0.140 |
Why?
|
| Lung | 1 | 2005 | 1487 | 0.140 |
Why?
|
| Malpractice | 1 | 1998 | 55 | 0.140 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2017 | 96 | 0.140 |
Why?
|
| Thioridazine | 2 | 2008 | 3 | 0.140 |
Why?
|
| Vaccination | 2 | 2022 | 953 | 0.140 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 149 | 0.140 |
Why?
|
| Head Injuries, Closed | 1 | 1997 | 44 | 0.140 |
Why?
|
| Demography | 3 | 2020 | 240 | 0.140 |
Why?
|
| History, 21st Century | 1 | 2018 | 267 | 0.140 |
Why?
|
| Ethanol | 1 | 2018 | 163 | 0.140 |
Why?
|
| Neuronal Ceroid-Lipofuscinoses | 2 | 1988 | 13 | 0.140 |
Why?
|
| Dopamine D2 Receptor Antagonists | 2 | 2015 | 3 | 0.140 |
Why?
|
| Symporters | 1 | 2017 | 69 | 0.140 |
Why?
|
| Benzylamines | 1 | 2017 | 15 | 0.140 |
Why?
|
| Sirolimus | 2 | 2009 | 223 | 0.140 |
Why?
|
| Societies, Medical | 2 | 2019 | 690 | 0.140 |
Why?
|
| Adenylyl Cyclases | 1 | 2017 | 83 | 0.140 |
Why?
|
| Carotid Artery Injuries | 1 | 1997 | 40 | 0.140 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 547 | 0.140 |
Why?
|
| Midodrine | 2 | 1994 | 3 | 0.140 |
Why?
|
| Neurofibrillary Tangles | 2 | 2015 | 26 | 0.140 |
Why?
|
| Microelectrodes | 3 | 2011 | 42 | 0.140 |
Why?
|
| alpha Catenin | 1 | 2016 | 6 | 0.140 |
Why?
|
| Strabismus | 1 | 2017 | 48 | 0.140 |
Why?
|
| Polysomnography | 1 | 2018 | 145 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 353 | 0.130 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2016 | 39 | 0.130 |
Why?
|
| Muscle Relaxants, Central | 2 | 2013 | 32 | 0.130 |
Why?
|
| Data Collection | 2 | 2013 | 382 | 0.130 |
Why?
|
| Proteomics | 3 | 2010 | 501 | 0.130 |
Why?
|
| Electrophysiology | 4 | 2004 | 271 | 0.130 |
Why?
|
| Developmental Disabilities | 2 | 2022 | 712 | 0.130 |
Why?
|
| Alanine | 1 | 2017 | 182 | 0.130 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2019 | 23 | 0.130 |
Why?
|
| Comprehension | 1 | 2016 | 75 | 0.130 |
Why?
|
| Patient Positioning | 1 | 2016 | 54 | 0.130 |
Why?
|
| Texas | 4 | 2010 | 3579 | 0.130 |
Why?
|
| Propofol | 1 | 1996 | 43 | 0.130 |
Why?
|
| Positron-Emission Tomography | 2 | 2011 | 297 | 0.130 |
Why?
|
| Vitamins | 1 | 2016 | 108 | 0.130 |
Why?
|
| Monoamine Oxidase Inhibitors | 2 | 2009 | 11 | 0.130 |
Why?
|
| Linear Models | 4 | 2014 | 667 | 0.130 |
Why?
|
| Autopsy | 3 | 2010 | 111 | 0.130 |
Why?
|
| Microsatellite Repeats | 4 | 2012 | 220 | 0.130 |
Why?
|
| Synaptic Vesicles | 1 | 2016 | 64 | 0.130 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2011 | 142 | 0.130 |
Why?
|
| Piperidines | 1 | 2017 | 204 | 0.130 |
Why?
|
| Dihydroergotamine | 1 | 2015 | 10 | 0.130 |
Why?
|
| Tenascin | 1 | 2016 | 31 | 0.130 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2016 | 68 | 0.130 |
Why?
|
| Wounds, Gunshot | 1 | 1997 | 137 | 0.130 |
Why?
|
| RNA, Small Interfering | 5 | 2012 | 660 | 0.130 |
Why?
|
| Facial Paralysis | 2 | 1998 | 35 | 0.130 |
Why?
|
| Classification | 1 | 1995 | 18 | 0.130 |
Why?
|
| Critical Care | 1 | 2021 | 656 | 0.130 |
Why?
|
| Stem Cells | 1 | 2020 | 694 | 0.120 |
Why?
|
| Nortropanes | 1 | 2015 | 1 | 0.120 |
Why?
|
| Muscle Spasticity | 1 | 2016 | 73 | 0.120 |
Why?
|
| Early Diagnosis | 3 | 2012 | 180 | 0.120 |
Why?
|
| SAM Domain and HD Domain-Containing Protein 1 | 1 | 2015 | 5 | 0.120 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type III | 1 | 2015 | 6 | 0.120 |
Why?
|
| Minisatellite Repeats | 1 | 1995 | 42 | 0.120 |
Why?
|
| Placebos | 3 | 2006 | 240 | 0.120 |
Why?
|
| Sleep Stages | 3 | 2002 | 32 | 0.120 |
Why?
|
| Axonal Transport | 1 | 2015 | 22 | 0.120 |
Why?
|
| Rare Diseases | 1 | 2017 | 190 | 0.120 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2015 | 24 | 0.120 |
Why?
|
| Estrogens | 1 | 2018 | 514 | 0.120 |
Why?
|
| World Health Organization | 1 | 1995 | 101 | 0.120 |
Why?
|
| Mental Status Schedule | 2 | 2008 | 44 | 0.120 |
Why?
|
| Bolivia | 1 | 2015 | 15 | 0.120 |
Why?
|
| Hypnotics and Sedatives | 1 | 1996 | 136 | 0.120 |
Why?
|
| Eyelids | 3 | 2007 | 119 | 0.120 |
Why?
|
| Whipple Disease | 1 | 2014 | 6 | 0.120 |
Why?
|
| Emotions | 2 | 2011 | 350 | 0.120 |
Why?
|
| Neuroimaging | 1 | 2018 | 334 | 0.120 |
Why?
|
| Homozygote | 2 | 2010 | 548 | 0.120 |
Why?
|
| Telomere-Binding Proteins | 1 | 2015 | 43 | 0.120 |
Why?
|
| Cell Death | 2 | 2007 | 238 | 0.120 |
Why?
|
| Canada | 2 | 2016 | 300 | 0.120 |
Why?
|
| Histones | 2 | 2015 | 526 | 0.120 |
Why?
|
| Cognition | 5 | 2015 | 709 | 0.120 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 209 | 0.120 |
Why?
|
| MPTP Poisoning | 1 | 2014 | 3 | 0.120 |
Why?
|
| Receptors, Virus | 1 | 2015 | 107 | 0.120 |
Why?
|
| DNA Repeat Expansion | 1 | 2015 | 64 | 0.120 |
Why?
|
| Observational Studies as Topic | 1 | 2014 | 87 | 0.120 |
Why?
|
| Genes, p53 | 1 | 2015 | 212 | 0.120 |
Why?
|
| Presynaptic Terminals | 2 | 2005 | 76 | 0.120 |
Why?
|
| Exome | 2 | 2017 | 1033 | 0.110 |
Why?
|
| Insecticides | 3 | 2011 | 52 | 0.110 |
Why?
|
| Methadone | 1 | 2015 | 126 | 0.110 |
Why?
|
| Tetanus Toxin | 4 | 2011 | 26 | 0.110 |
Why?
|
| Neural Inhibition | 2 | 2006 | 109 | 0.110 |
Why?
|
| Databases, Factual | 4 | 2021 | 1174 | 0.110 |
Why?
|
| Antioxidants | 2 | 2011 | 335 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 1999 | 774 | 0.110 |
Why?
|
| Brain Mapping | 2 | 2015 | 397 | 0.110 |
Why?
|
| Epitope Mapping | 4 | 2017 | 80 | 0.110 |
Why?
|
| Genetic Linkage | 4 | 2006 | 453 | 0.110 |
Why?
|
| Genetic Vectors | 2 | 2015 | 939 | 0.110 |
Why?
|
| Muscle Cramp | 1 | 1993 | 3 | 0.110 |
Why?
|
| Eyebrows | 2 | 2007 | 13 | 0.110 |
Why?
|
| Research | 1 | 2015 | 263 | 0.110 |
Why?
|
| Dependovirus | 2 | 2015 | 127 | 0.110 |
Why?
|
| Neuropeptides | 1 | 2014 | 113 | 0.110 |
Why?
|
| Odds Ratio | 4 | 2014 | 1252 | 0.110 |
Why?
|
| Ophthalmoplegia | 2 | 1993 | 54 | 0.110 |
Why?
|
| Hereditary Sensory and Motor Neuropathy | 1 | 1993 | 36 | 0.110 |
Why?
|
| Proteasome Inhibitors | 2 | 2010 | 61 | 0.110 |
Why?
|
| Hydroxyindoleacetic Acid | 3 | 1999 | 28 | 0.110 |
Why?
|
| Exercise | 1 | 1999 | 787 | 0.110 |
Why?
|
| Uterine Cervical Diseases | 1 | 1993 | 6 | 0.110 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 1348 | 0.110 |
Why?
|
| Gene Expression | 4 | 2012 | 1560 | 0.110 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2013 | 106 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 1999 | 662 | 0.110 |
Why?
|
| Lewy Bodies | 2 | 2006 | 11 | 0.110 |
Why?
|
| DNA, Mitochondrial | 3 | 2003 | 210 | 0.110 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1994 | 369 | 0.110 |
Why?
|
| Nitriles | 2 | 2011 | 146 | 0.100 |
Why?
|
| Organ Specificity | 2 | 2012 | 427 | 0.100 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2012 | 8 | 0.100 |
Why?
|
| Cardiovascular Physiological Phenomena | 2 | 2005 | 29 | 0.100 |
Why?
|
| Adrenal Medulla | 2 | 1989 | 8 | 0.100 |
Why?
|
| Receptor, Serotonin, 5-HT2B | 1 | 2012 | 1 | 0.100 |
Why?
|
| Neoplasms | 1 | 2007 | 2764 | 0.100 |
Why?
|
| Gastroesophageal Reflux | 2 | 2007 | 295 | 0.100 |
Why?
|
| Temperature | 1 | 2013 | 303 | 0.100 |
Why?
|
| Uncoupling Agents | 2 | 2010 | 4 | 0.100 |
Why?
|
| Observer Variation | 2 | 2011 | 299 | 0.100 |
Why?
|
| Athetosis | 1 | 1992 | 1 | 0.100 |
Why?
|
| Cluster Analysis | 2 | 2024 | 398 | 0.100 |
Why?
|
| Phenols | 2 | 2003 | 55 | 0.100 |
Why?
|
| Flavonoids | 2 | 2003 | 77 | 0.100 |
Why?
|
| Hashimoto Disease | 1 | 2012 | 21 | 0.100 |
Why?
|
| Reflex | 1 | 1992 | 51 | 0.100 |
Why?
|
| Equipment Failure | 1 | 2012 | 122 | 0.100 |
Why?
|
| Rett Syndrome | 4 | 2003 | 291 | 0.100 |
Why?
|
| Language | 3 | 2011 | 200 | 0.100 |
Why?
|
| Homovanillic Acid | 2 | 1989 | 25 | 0.100 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2012 | 32 | 0.100 |
Why?
|
| Auditory Perception | 1 | 1992 | 37 | 0.100 |
Why?
|
| Perphenazine | 2 | 2008 | 6 | 0.100 |
Why?
|
| Diaphragm | 1 | 2012 | 98 | 0.100 |
Why?
|
| Nerve Block | 1 | 2013 | 64 | 0.100 |
Why?
|
| Nystagmus, Optokinetic | 1 | 2011 | 3 | 0.100 |
Why?
|
| Patient Selection | 2 | 2006 | 690 | 0.100 |
Why?
|
| Amitriptyline | 2 | 2008 | 27 | 0.100 |
Why?
|
| Pursuit, Smooth | 1 | 2011 | 10 | 0.100 |
Why?
|
| Saccades | 1 | 2011 | 19 | 0.100 |
Why?
|
| Flecainide | 1 | 1992 | 23 | 0.100 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2013 | 149 | 0.100 |
Why?
|
| Haloperidol | 2 | 2008 | 23 | 0.100 |
Why?
|
| Ultraviolet Rays | 1 | 2012 | 203 | 0.100 |
Why?
|
| Pharmacogenetics | 1 | 2012 | 184 | 0.100 |
Why?
|
| Placebo Effect | 1 | 2011 | 25 | 0.090 |
Why?
|
| Muscle Denervation | 2 | 2006 | 7 | 0.090 |
Why?
|
| DNA Copy Number Variations | 2 | 2014 | 947 | 0.090 |
Why?
|
| Tachycardia | 1 | 1992 | 70 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 241 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 1031 | 0.090 |
Why?
|
| Motor Neurons | 2 | 2003 | 141 | 0.090 |
Why?
|
| Extremities | 2 | 2012 | 82 | 0.090 |
Why?
|
| Family | 2 | 2019 | 562 | 0.090 |
Why?
|
| Nitric Oxide | 2 | 2005 | 444 | 0.090 |
Why?
|
| Chi-Square Distribution | 4 | 2014 | 585 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 1942 | 0.090 |
Why?
|
| Xerostomia | 1 | 2011 | 8 | 0.090 |
Why?
|
| Apolipoproteins E | 4 | 2008 | 189 | 0.090 |
Why?
|
| Cocaine | 1 | 1993 | 207 | 0.090 |
Why?
|
| Chemokine CX3CL1 | 1 | 2011 | 3 | 0.090 |
Why?
|
| Spinal Cord Injuries | 1 | 1994 | 311 | 0.090 |
Why?
|
| Alcohol Drinking | 2 | 2010 | 344 | 0.090 |
Why?
|
| Adalimumab | 1 | 2011 | 26 | 0.090 |
Why?
|
| Celiac Disease | 1 | 2012 | 68 | 0.090 |
Why?
|
| Complement Factor H | 1 | 2011 | 21 | 0.090 |
Why?
|
| Social Behavior | 3 | 2008 | 209 | 0.090 |
Why?
|
| Stilbenes | 1 | 2011 | 36 | 0.090 |
Why?
|
| Hydrocephalus | 2 | 2002 | 242 | 0.090 |
Why?
|
| RNA, Messenger | 4 | 2020 | 2815 | 0.090 |
Why?
|
| Mass Spectrometry | 2 | 2010 | 329 | 0.090 |
Why?
|
| Complement C3 | 1 | 2011 | 48 | 0.090 |
Why?
|
| Neurology | 2 | 2006 | 107 | 0.090 |
Why?
|
| PubMed | 1 | 2011 | 20 | 0.090 |
Why?
|
| Attention | 1 | 1992 | 193 | 0.090 |
Why?
|
| Immunity, Humoral | 1 | 2011 | 70 | 0.090 |
Why?
|
| Sjogren's Syndrome | 1 | 2012 | 89 | 0.090 |
Why?
|
| Pyridones | 1 | 2011 | 110 | 0.090 |
Why?
|
| Ubiquitin | 2 | 2010 | 141 | 0.090 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2008 | 60 | 0.090 |
Why?
|
| Genetic Counseling | 2 | 2006 | 220 | 0.090 |
Why?
|
| Oxygen Consumption | 2 | 2004 | 304 | 0.090 |
Why?
|
| Catheter Ablation | 1 | 2013 | 240 | 0.090 |
Why?
|
| Glutamate Decarboxylase | 1 | 1991 | 37 | 0.090 |
Why?
|
| Reference Values | 5 | 2006 | 711 | 0.090 |
Why?
|
| Neuronal Plasticity | 1 | 2013 | 273 | 0.090 |
Why?
|
| Multivariate Analysis | 2 | 2006 | 1422 | 0.090 |
Why?
|
| Hypertension | 1 | 2019 | 1318 | 0.090 |
Why?
|
| HLA-DQ Antigens | 1 | 2010 | 21 | 0.090 |
Why?
|
| Catechols | 1 | 2010 | 9 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 414 | 0.090 |
Why?
|
| Deferoxamine | 1 | 2010 | 7 | 0.090 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2011 | 196 | 0.090 |
Why?
|
| Antidotes | 1 | 2010 | 12 | 0.090 |
Why?
|
| Pneumonia, Aspiration | 1 | 2010 | 18 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 10 | 2012 | 4401 | 0.090 |
Why?
|
| Quinolones | 1 | 2010 | 53 | 0.090 |
Why?
|
| Cranial Nerve Diseases | 1 | 1990 | 26 | 0.090 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2011 | 116 | 0.090 |
Why?
|
| Sulpiride | 1 | 1990 | 5 | 0.090 |
Why?
|
| Sweating Sickness | 1 | 2009 | 1 | 0.080 |
Why?
|
| Dermatitis, Seborrheic | 1 | 2009 | 3 | 0.080 |
Why?
|
| Gliosis | 1 | 2010 | 29 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 6 | 3 | 2006 | 142 | 0.080 |
Why?
|
| Linkage Disequilibrium | 4 | 2003 | 309 | 0.080 |
Why?
|
| Phenothiazines | 1 | 1989 | 5 | 0.080 |
Why?
|
| Palatal Muscles | 1 | 2009 | 1 | 0.080 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2011 | 163 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 674 | 0.080 |
Why?
|
| Cross-Cultural Comparison | 2 | 2007 | 59 | 0.080 |
Why?
|
| Apoferritins | 1 | 2009 | 4 | 0.080 |
Why?
|
| After-Hours Care | 1 | 2009 | 3 | 0.080 |
Why?
|
| Vocal Cords | 2 | 2003 | 65 | 0.080 |
Why?
|
| Language Disorders | 1 | 2009 | 24 | 0.080 |
Why?
|
| Brain Tissue Transplantation | 2 | 2001 | 3 | 0.080 |
Why?
|
| Neuropharmacology | 1 | 2009 | 3 | 0.080 |
Why?
|
| Synapses | 2 | 2005 | 455 | 0.080 |
Why?
|
| Pregabalin | 1 | 2009 | 4 | 0.080 |
Why?
|
| DNA | 2 | 1996 | 1595 | 0.080 |
Why?
|
| Synaptosomal-Associated Protein 25 | 2 | 2011 | 12 | 0.080 |
Why?
|
| Pain Management | 1 | 2011 | 175 | 0.080 |
Why?
|
| Mesencephalon | 2 | 1999 | 42 | 0.080 |
Why?
|
| Urinary Bladder Diseases | 1 | 2009 | 35 | 0.080 |
Why?
|
| Mice, Knockout | 7 | 2008 | 3727 | 0.080 |
Why?
|
| Incidence | 2 | 2011 | 3135 | 0.080 |
Why?
|
| Australia | 3 | 2017 | 139 | 0.080 |
Why?
|
| Streptococcal Infections | 1 | 2012 | 243 | 0.080 |
Why?
|
| Whole Genome Sequencing | 2 | 2022 | 277 | 0.080 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2010 | 50 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1228 | 0.080 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2009 | 14 | 0.080 |
Why?
|
| Time | 2 | 2007 | 93 | 0.080 |
Why?
|
| Databases, Bibliographic | 1 | 2009 | 19 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2017 | 813 | 0.080 |
Why?
|
| Scientific Misconduct | 1 | 2009 | 6 | 0.080 |
Why?
|
| Europe | 4 | 2021 | 352 | 0.080 |
Why?
|
| Electrodes | 2 | 2007 | 98 | 0.080 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2009 | 78 | 0.080 |
Why?
|
| Short Interspersed Nucleotide Elements | 1 | 2008 | 17 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2014 | 517 | 0.080 |
Why?
|
| Receptors, CXCR3 | 1 | 2008 | 21 | 0.080 |
Why?
|
| Retroelements | 1 | 2008 | 40 | 0.080 |
Why?
|
| Psychotherapy | 1 | 2011 | 229 | 0.080 |
Why?
|
| Piperazines | 1 | 2010 | 236 | 0.080 |
Why?
|
| Birth Injuries | 2 | 2007 | 22 | 0.080 |
Why?
|
| Genes, X-Linked | 1 | 2008 | 59 | 0.080 |
Why?
|
| Glycols | 1 | 1988 | 6 | 0.080 |
Why?
|
| Mood Disorders | 1 | 2009 | 122 | 0.080 |
Why?
|
| Methoxyhydroxyphenylglycol | 1 | 1988 | 35 | 0.080 |
Why?
|
| Receptors, Adenosine A2 | 1 | 2008 | 3 | 0.070 |
Why?
|
| Fetal Tissue Transplantation | 2 | 1999 | 16 | 0.070 |
Why?
|
| Memory, Short-Term | 1 | 2009 | 140 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2005 | 2089 | 0.070 |
Why?
|
| Factor Analysis, Statistical | 2 | 2024 | 237 | 0.070 |
Why?
|
| Methyldopa | 1 | 2008 | 4 | 0.070 |
Why?
|
| Cell Line | 6 | 2014 | 2748 | 0.070 |
Why?
|
| Larynx | 2 | 2005 | 70 | 0.070 |
Why?
|
| Subacute Sclerosing Panencephalitis | 1 | 1988 | 2 | 0.070 |
Why?
|
| Causality | 1 | 2008 | 83 | 0.070 |
Why?
|
| Touch | 2 | 2021 | 34 | 0.070 |
Why?
|
| Reserpine | 1 | 1987 | 12 | 0.070 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2008 | 22 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2008 | 256 | 0.070 |
Why?
|
| Protein Binding | 4 | 2015 | 1738 | 0.070 |
Why?
|
| Amino Acid Substitution | 2 | 2009 | 391 | 0.070 |
Why?
|
| Facial Hemiatrophy | 1 | 2007 | 3 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2006 | 120 | 0.070 |
Why?
|
| Body Weight | 1 | 1992 | 995 | 0.070 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 3 | 2000 | 7 | 0.070 |
Why?
|
| Locomotion | 1 | 2008 | 68 | 0.070 |
Why?
|
| Hemorrhage | 1 | 2011 | 467 | 0.070 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 262 | 0.070 |
Why?
|
| Facial Nerve Diseases | 1 | 2007 | 6 | 0.070 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 307 | 0.070 |
Why?
|
| Chin | 1 | 2007 | 4 | 0.070 |
Why?
|
| Ammonia | 1 | 1988 | 74 | 0.070 |
Why?
|
| Social Behavior Disorders | 1 | 1987 | 12 | 0.070 |
Why?
|
| Facial Nerve | 1 | 2007 | 24 | 0.070 |
Why?
|
| Publishing | 1 | 2009 | 109 | 0.070 |
Why?
|
| Histone Acetyltransferases | 1 | 2008 | 314 | 0.070 |
Why?
|
| Forehead | 1 | 2007 | 13 | 0.070 |
Why?
|
| Sympathetic Nervous System | 1 | 2007 | 63 | 0.070 |
Why?
|
| Seizures, Febrile | 1 | 2007 | 24 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2010 | 368 | 0.070 |
Why?
|
| DNA Primers | 2 | 2006 | 657 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2011 | 970 | 0.070 |
Why?
|
| Blindness | 1 | 1988 | 72 | 0.070 |
Why?
|
| Risk | 4 | 2013 | 754 | 0.070 |
Why?
|
| Cysteine Proteinase Inhibitors | 3 | 2012 | 40 | 0.070 |
Why?
|
| Tomography, Optical Coherence | 2 | 2023 | 516 | 0.070 |
Why?
|
| Motorcycles | 1 | 2007 | 7 | 0.070 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2007 | 36 | 0.070 |
Why?
|
| Dibenzoxazepines | 1 | 1987 | 1 | 0.070 |
Why?
|
| Loxapine | 1 | 1987 | 1 | 0.070 |
Why?
|
| Schizophrenia, Paranoid | 1 | 1987 | 9 | 0.070 |
Why?
|
| Singapore | 1 | 2006 | 16 | 0.070 |
Why?
|
| Photography | 1 | 2008 | 95 | 0.070 |
Why?
|
| Hematologic Diseases | 1 | 1988 | 75 | 0.070 |
Why?
|
| Scoliosis | 2 | 2007 | 133 | 0.070 |
Why?
|
| Sequence Analysis | 1 | 2006 | 53 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2011 | 777 | 0.070 |
Why?
|
| Nitric Oxide Synthase | 2 | 2004 | 186 | 0.070 |
Why?
|
| Carbamazepine | 1 | 2006 | 48 | 0.070 |
Why?
|
| Age Distribution | 2 | 2009 | 415 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2008 | 406 | 0.070 |
Why?
|
| Mastication | 2 | 2000 | 6 | 0.070 |
Why?
|
| Oncogenes | 1 | 2007 | 167 | 0.070 |
Why?
|
| Health Planning Guidelines | 1 | 2006 | 32 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 2 | 2 | 2006 | 118 | 0.070 |
Why?
|
| Isoenzymes | 3 | 2003 | 229 | 0.070 |
Why?
|
| Blood-Brain Barrier | 1 | 2007 | 142 | 0.070 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2007 | 205 | 0.070 |
Why?
|
| Contraindications | 1 | 2006 | 78 | 0.070 |
Why?
|
| France | 1 | 2006 | 80 | 0.070 |
Why?
|
| Immunoassay | 1 | 2007 | 130 | 0.070 |
Why?
|
| Ligases | 2 | 2003 | 46 | 0.070 |
Why?
|
| Tea | 2 | 2003 | 15 | 0.070 |
Why?
|
| Liver | 1 | 2013 | 1735 | 0.070 |
Why?
|
| Myasthenia Gravis | 1 | 1987 | 73 | 0.060 |
Why?
|
| Cation Transport Proteins | 2 | 2009 | 93 | 0.060 |
Why?
|
| Cervical Vertebrae | 2 | 1997 | 114 | 0.060 |
Why?
|
| Arylamine N-Acetyltransferase | 2 | 2003 | 8 | 0.060 |
Why?
|
| 3' Untranslated Regions | 1 | 2006 | 164 | 0.060 |
Why?
|
| Medical History Taking | 1 | 2006 | 108 | 0.060 |
Why?
|
| Life Change Events | 1 | 2006 | 57 | 0.060 |
Why?
|
| Transplants | 1 | 2006 | 35 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2015 | 8189 | 0.060 |
Why?
|
| Middle East | 2 | 2021 | 34 | 0.060 |
Why?
|
| Sequence Alignment | 3 | 2015 | 621 | 0.060 |
Why?
|
| Crime | 1 | 2006 | 26 | 0.060 |
Why?
|
| Salivation | 1 | 2005 | 6 | 0.060 |
Why?
|
| Weight Loss | 1 | 2009 | 480 | 0.060 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2005 | 17 | 0.060 |
Why?
|
| Glutathione Transferase | 2 | 2003 | 153 | 0.060 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2005 | 68 | 0.060 |
Why?
|
| Electrocardiography | 1 | 2011 | 971 | 0.060 |
Why?
|
| Oropharynx | 1 | 2005 | 34 | 0.060 |
Why?
|
| Reflex, Pupillary | 1 | 2005 | 15 | 0.060 |
Why?
|
| Myocarditis | 1 | 2007 | 131 | 0.060 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2006 | 44 | 0.060 |
Why?
|
| Action Potentials | 2 | 2010 | 500 | 0.060 |
Why?
|
| Restraint, Physical | 1 | 2005 | 24 | 0.060 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2006 | 141 | 0.060 |
Why?
|
| Behavior, Addictive | 1 | 2006 | 58 | 0.060 |
Why?
|
| Periodicity | 1 | 2005 | 55 | 0.060 |
Why?
|
| Antisocial Personality Disorder | 1 | 2006 | 63 | 0.060 |
Why?
|
| Spinal Diseases | 1 | 2005 | 45 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2007 | 681 | 0.060 |
Why?
|
| Guidelines as Topic | 1 | 2006 | 196 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2008 | 428 | 0.060 |
Why?
|
| Delayed-Action Preparations | 2 | 2020 | 110 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2012 | 808 | 0.060 |
Why?
|
| Coenzymes | 1 | 2005 | 11 | 0.060 |
Why?
|
| Self Report | 2 | 2018 | 512 | 0.060 |
Why?
|
| Dysarthria | 3 | 2013 | 21 | 0.060 |
Why?
|
| N-Methylaspartate | 1 | 2005 | 29 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2008 | 1068 | 0.060 |
Why?
|
| Cell Count | 4 | 2010 | 252 | 0.060 |
Why?
|
| Sarcoglycans | 1 | 2004 | 7 | 0.060 |
Why?
|
| Selection Bias | 1 | 2004 | 22 | 0.060 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2025 | 62 | 0.060 |
Why?
|
| Primidone | 3 | 2003 | 9 | 0.060 |
Why?
|
| Cyclooxygenase 1 | 1 | 2005 | 40 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2006 | 372 | 0.060 |
Why?
|
| Neuroblastoma | 3 | 2008 | 520 | 0.060 |
Why?
|
| Vitamin E | 1 | 2005 | 67 | 0.060 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2005 | 64 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2005 | 61 | 0.060 |
Why?
|
| Molecular Structure | 1 | 2005 | 288 | 0.060 |
Why?
|
| R-SNARE Proteins | 1 | 2004 | 9 | 0.060 |
Why?
|
| Qa-SNARE Proteins | 1 | 2004 | 20 | 0.060 |
Why?
|
| Rats | 5 | 2011 | 3676 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2007 | 388 | 0.060 |
Why?
|
| Pain Measurement | 3 | 2014 | 352 | 0.060 |
Why?
|
| Caspase Inhibitors | 1 | 2004 | 31 | 0.060 |
Why?
|
| Protein Subunits | 1 | 2005 | 164 | 0.060 |
Why?
|
| Spinal Osteophytosis | 1 | 2004 | 5 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2011 | 337 | 0.060 |
Why?
|
| Cell Proliferation | 3 | 2017 | 2286 | 0.060 |
Why?
|
| ROC Curve | 3 | 2013 | 566 | 0.060 |
Why?
|
| Arginine | 1 | 2006 | 331 | 0.060 |
Why?
|
| Health Status | 1 | 2006 | 371 | 0.060 |
Why?
|
| Factitious Disorders | 1 | 2004 | 1 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 159 | 0.060 |
Why?
|
| Precipitin Tests | 2 | 2005 | 152 | 0.060 |
Why?
|
| Contingent Negative Variation | 1 | 2003 | 2 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2004 | 95 | 0.060 |
Why?
|
| Gastrointestinal Motility | 1 | 2004 | 45 | 0.060 |
Why?
|
| Nervous System | 2 | 2013 | 127 | 0.060 |
Why?
|
| Auditory Threshold | 1 | 2003 | 17 | 0.060 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 2004 | 124 | 0.060 |
Why?
|
| Prodrugs | 1 | 2004 | 59 | 0.050 |
Why?
|
| Audiometry | 1 | 2003 | 21 | 0.050 |
Why?
|
| Shoulder | 1 | 2003 | 27 | 0.050 |
Why?
|
| Esophagus | 1 | 2005 | 216 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2022 | 485 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2005 | 245 | 0.050 |
Why?
|
| Pharynx | 1 | 2003 | 64 | 0.050 |
Why?
|
| Recurrence | 2 | 2001 | 1421 | 0.050 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 593 | 0.050 |
Why?
|
| Synaptic Transmission | 1 | 2006 | 350 | 0.050 |
Why?
|
| NADH Dehydrogenase | 1 | 2003 | 6 | 0.050 |
Why?
|
| Group VI Phospholipases A2 | 1 | 2023 | 9 | 0.050 |
Why?
|
| Drug Storage | 1 | 2003 | 17 | 0.050 |
Why?
|
| Biological Transport | 1 | 2004 | 347 | 0.050 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2011 | 123 | 0.050 |
Why?
|
| Genome, Human | 2 | 2011 | 1260 | 0.050 |
Why?
|
| Microfilament Proteins | 1 | 2005 | 273 | 0.050 |
Why?
|
| Cell Culture Techniques | 2 | 2003 | 282 | 0.050 |
Why?
|
| Psychometrics | 1 | 2007 | 666 | 0.050 |
Why?
|
| Encephalitis, Viral | 1 | 2003 | 20 | 0.050 |
Why?
|
| Site-Specific DNA-Methyltransferase (Adenine-Specific) | 1 | 2022 | 11 | 0.050 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2003 | 34 | 0.050 |
Why?
|
| Mental Processes | 3 | 2011 | 40 | 0.050 |
Why?
|
| Mitochondria | 2 | 2009 | 680 | 0.050 |
Why?
|
| Phosphatidylinositols | 1 | 2022 | 31 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2004 | 256 | 0.050 |
Why?
|
| Monitoring, Intraoperative | 1 | 2003 | 128 | 0.050 |
Why?
|
| Aging | 2 | 2005 | 1165 | 0.050 |
Why?
|
| Models, Animal | 2 | 2003 | 460 | 0.050 |
Why?
|
| International Classification of Diseases | 1 | 2023 | 90 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2003 | 302 | 0.050 |
Why?
|
| Interview, Psychological | 1 | 2002 | 96 | 0.050 |
Why?
|
| Kernicterus | 1 | 2002 | 1 | 0.050 |
Why?
|
| Red Nucleus | 1 | 2002 | 2 | 0.050 |
Why?
|
| Polymers | 1 | 2003 | 106 | 0.050 |
Why?
|
| Collagen | 1 | 2003 | 316 | 0.050 |
Why?
|
| Health Status Indicators | 2 | 2004 | 122 | 0.050 |
Why?
|
| 1-Methyl-4-phenylpyridinium | 2 | 2003 | 4 | 0.050 |
Why?
|
| Multifactorial Inheritance | 2 | 2019 | 138 | 0.050 |
Why?
|
| Dihydroxyphenylalanine | 1 | 2001 | 8 | 0.050 |
Why?
|
| Computers | 1 | 2022 | 68 | 0.050 |
Why?
|
| Fluorine Radioisotopes | 1 | 2001 | 11 | 0.050 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2001 | 22 | 0.050 |
Why?
|
| Physical Exertion | 1 | 2002 | 79 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2022 | 461 | 0.050 |
Why?
|
| Chromosomes, Human | 1 | 2002 | 129 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2008 | 172 | 0.050 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 1 | 2021 | 9 | 0.050 |
Why?
|
| Plant Extracts | 1 | 2003 | 119 | 0.050 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2011 | 106 | 0.050 |
Why?
|
| Automobile Driving | 1 | 2001 | 27 | 0.050 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2001 | 18 | 0.050 |
Why?
|
| Caregivers | 1 | 2006 | 556 | 0.050 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2003 | 210 | 0.050 |
Why?
|
| Stomach | 1 | 2003 | 271 | 0.050 |
Why?
|
| Risk Assessment | 5 | 2011 | 3429 | 0.050 |
Why?
|
| Random Allocation | 2 | 1999 | 436 | 0.050 |
Why?
|
| Monoamine Oxidase | 2 | 2000 | 11 | 0.050 |
Why?
|
| Immune Sera | 2 | 2011 | 95 | 0.050 |
Why?
|
| Logistic Models | 2 | 2018 | 1800 | 0.050 |
Why?
|
| Bromocriptine | 1 | 2001 | 6 | 0.050 |
Why?
|
| Sweating | 1 | 2001 | 7 | 0.050 |
Why?
|
| Arnold-Chiari Malformation | 1 | 2002 | 50 | 0.050 |
Why?
|
| Introns | 1 | 2002 | 299 | 0.050 |
Why?
|
| Electrocoagulation | 2 | 2001 | 36 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2007 | 728 | 0.050 |
Why?
|
| Contracture | 1 | 2001 | 24 | 0.050 |
Why?
|
| Chromosome Mapping | 4 | 2006 | 1079 | 0.040 |
Why?
|
| Asia | 1 | 2021 | 107 | 0.040 |
Why?
|
| Hybrid Cells | 2 | 1999 | 80 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2016 | 656 | 0.040 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2021 | 92 | 0.040 |
Why?
|
| Facial Expression | 1 | 2001 | 27 | 0.040 |
Why?
|
| Adenosine Triphosphatases | 1 | 2001 | 200 | 0.040 |
Why?
|
| Nausea | 1 | 2001 | 83 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 336 | 0.040 |
Why?
|
| Antigens, Bacterial | 1 | 2002 | 314 | 0.040 |
Why?
|
| Tooth Abrasion | 1 | 2000 | 1 | 0.040 |
Why?
|
| Masseter Muscle | 1 | 2000 | 5 | 0.040 |
Why?
|
| Masticatory Muscles | 1 | 1999 | 2 | 0.040 |
Why?
|
| Free Radical Scavengers | 1 | 2000 | 49 | 0.040 |
Why?
|
| Receptors, Dopamine D2 | 3 | 2000 | 45 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 1892 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2000 | 87 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2000 | 143 | 0.040 |
Why?
|
| Edema | 1 | 2001 | 135 | 0.040 |
Why?
|
| Reoperation | 2 | 2007 | 831 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2022 | 464 | 0.040 |
Why?
|
| Base Sequence | 3 | 2005 | 3089 | 0.040 |
Why?
|
| Administration, Sublingual | 1 | 1999 | 12 | 0.040 |
Why?
|
| Palliative Care | 1 | 2023 | 427 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2007 | 1010 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2003 | 1491 | 0.040 |
Why?
|
| Mandible | 1 | 2000 | 79 | 0.040 |
Why?
|
| Mitochondrial Membranes | 1 | 2019 | 30 | 0.040 |
Why?
|
| Professional Competence | 1 | 2000 | 95 | 0.040 |
Why?
|
| Drug Compounding | 1 | 1999 | 36 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 570 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2011 | 243 | 0.040 |
Why?
|
| Thalamic Diseases | 1 | 1998 | 3 | 0.040 |
Why?
|
| GABA-B Receptor Agonists | 1 | 2018 | 2 | 0.040 |
Why?
|
| Mice, Inbred ICR | 2 | 2011 | 152 | 0.040 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 2 | 2011 | 22 | 0.040 |
Why?
|
| Trigeminal Neuralgia | 1 | 1998 | 10 | 0.040 |
Why?
|
| GTP Cyclohydrolase | 1 | 2018 | 5 | 0.040 |
Why?
|
| Quality Control | 2 | 2011 | 119 | 0.040 |
Why?
|
| Cerebrospinal Fluid | 2 | 2010 | 94 | 0.040 |
Why?
|
| Microscopy, Electron | 2 | 2010 | 393 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2011 | 60 | 0.040 |
Why?
|
| Codon, Nonsense | 1 | 2019 | 131 | 0.040 |
Why?
|
| Genes, Dominant | 1 | 2019 | 245 | 0.040 |
Why?
|
| Torso | 1 | 2018 | 11 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2003 | 875 | 0.040 |
Why?
|
| Oxidative Stress | 2 | 2003 | 800 | 0.040 |
Why?
|
| Acoustic Stimulation | 2 | 2004 | 85 | 0.040 |
Why?
|
| Lod Score | 3 | 2003 | 120 | 0.040 |
Why?
|
| Work Capacity Evaluation | 1 | 1998 | 1 | 0.040 |
Why?
|
| Prednisone | 2 | 1991 | 275 | 0.040 |
Why?
|
| Environmental Pollutants | 1 | 1999 | 69 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2003 | 816 | 0.040 |
Why?
|
| Range of Motion, Articular | 1 | 2018 | 68 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2010 | 1688 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2005 | 1890 | 0.040 |
Why?
|
| Neurogenesis | 1 | 2020 | 189 | 0.040 |
Why?
|
| Cytochromes c | 2 | 2009 | 51 | 0.040 |
Why?
|
| Peptide Mapping | 2 | 2008 | 44 | 0.040 |
Why?
|
| Counseling | 1 | 2019 | 216 | 0.040 |
Why?
|
| Tunisia | 2 | 2007 | 4 | 0.030 |
Why?
|
| Photic Stimulation | 2 | 2011 | 223 | 0.030 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 866 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2010 | 152 | 0.030 |
Why?
|
| Radio Waves | 1 | 1997 | 7 | 0.030 |
Why?
|
| Weight Gain | 1 | 2000 | 404 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2001 | 106 | 0.030 |
Why?
|
| Parietal Lobe | 1 | 1997 | 47 | 0.030 |
Why?
|
| Disabled Persons | 1 | 1998 | 93 | 0.030 |
Why?
|
| Spinal Canal | 1 | 1996 | 5 | 0.030 |
Why?
|
| Carotid Artery, Common | 1 | 1997 | 73 | 0.030 |
Why?
|
| Intervertebral Disc Displacement | 1 | 1996 | 18 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 205 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2016 | 20 | 0.030 |
Why?
|
| Psychoses, Substance-Induced | 1 | 1996 | 9 | 0.030 |
Why?
|
| Neuroleptic Malignant Syndrome | 1 | 1996 | 5 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 1997 | 205 | 0.030 |
Why?
|
| Conscious Sedation | 1 | 1996 | 62 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 101 | 0.030 |
Why?
|
| Synucleins | 3 | 2000 | 13 | 0.030 |
Why?
|
| Transcriptome | 1 | 2022 | 950 | 0.030 |
Why?
|
| Psychiatry | 1 | 1999 | 262 | 0.030 |
Why?
|
| Protein Domains | 1 | 2016 | 237 | 0.030 |
Why?
|
| Tooth Injuries | 1 | 1995 | 4 | 0.030 |
Why?
|
| Hallucinogens | 1 | 1996 | 42 | 0.030 |
Why?
|
| Arm Injuries | 1 | 1995 | 13 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2017 | 690 | 0.030 |
Why?
|
| Voice | 1 | 1995 | 14 | 0.030 |
Why?
|
| Protein Transport | 1 | 2016 | 368 | 0.030 |
Why?
|
| Psychological Tests | 1 | 1995 | 90 | 0.030 |
Why?
|
| Acetylation | 1 | 2015 | 166 | 0.030 |
Why?
|
| Neck Injuries | 1 | 1995 | 24 | 0.030 |
Why?
|
| Clozapine | 1 | 1995 | 22 | 0.030 |
Why?
|
| Orexins | 1 | 2014 | 7 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type I | 2 | 2005 | 31 | 0.030 |
Why?
|
| MEDLINE | 1 | 2014 | 20 | 0.030 |
Why?
|
| Cerebellar Ataxia | 1 | 2015 | 65 | 0.030 |
Why?
|
| Suppression, Genetic | 1 | 2014 | 43 | 0.030 |
Why?
|
| Affect | 1 | 1995 | 153 | 0.030 |
Why?
|
| Blood | 2 | 2010 | 104 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2008 | 427 | 0.030 |
Why?
|
| RNA, Untranslated | 1 | 2014 | 112 | 0.030 |
Why?
|
| Observation | 1 | 2014 | 42 | 0.030 |
Why?
|
| Carbon Monoxide Poisoning | 1 | 1993 | 7 | 0.030 |
Why?
|
| Naltrexone | 1 | 1994 | 70 | 0.030 |
Why?
|
| Syncope | 1 | 1994 | 52 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 757 | 0.030 |
Why?
|
| Antibody Specificity | 2 | 2008 | 202 | 0.030 |
Why?
|
| Longevity | 1 | 1995 | 137 | 0.030 |
Why?
|
| Transfection | 2 | 2008 | 1062 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2015 | 234 | 0.030 |
Why?
|
| Models, Genetic | 2 | 2010 | 759 | 0.030 |
Why?
|
| Vascular Surgical Procedures | 1 | 1998 | 575 | 0.030 |
Why?
|
| Sensation | 1 | 1993 | 56 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2015 | 442 | 0.030 |
Why?
|
| Polyphenols | 2 | 2003 | 19 | 0.030 |
Why?
|
| Rhinitis, Allergic | 1 | 2012 | 13 | 0.030 |
Why?
|
| Mental Health | 1 | 1996 | 343 | 0.030 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2014 | 202 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2003 | 64 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 579 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 747 | 0.020 |
Why?
|
| Space Flight | 1 | 1994 | 116 | 0.020 |
Why?
|
| Medical Records | 1 | 1993 | 189 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2003 | 78 | 0.020 |
Why?
|
| Cattle | 1 | 2013 | 565 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 1995 | 423 | 0.020 |
Why?
|
| Aphasia | 1 | 1992 | 13 | 0.020 |
Why?
|
| Iron-Regulatory Proteins | 1 | 2012 | 5 | 0.020 |
Why?
|
| Nucleus Accumbens | 1 | 2012 | 53 | 0.020 |
Why?
|
| Receptors, Transferrin | 1 | 2012 | 10 | 0.020 |
Why?
|
| Corpus Callosum | 1 | 1992 | 95 | 0.020 |
Why?
|
| Awareness | 1 | 1992 | 79 | 0.020 |
Why?
|
| Auditory Pathways | 1 | 1992 | 20 | 0.020 |
Why?
|
| Pediatrics | 1 | 2021 | 1159 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 409 | 0.020 |
Why?
|
| Cues | 1 | 2012 | 92 | 0.020 |
Why?
|
| Memory | 2 | 2011 | 363 | 0.020 |
Why?
|
| Monosomy | 1 | 1991 | 24 | 0.020 |
Why?
|
| Chromosome Segregation | 1 | 2011 | 63 | 0.020 |
Why?
|
| Exons | 2 | 2006 | 796 | 0.020 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2011 | 25 | 0.020 |
Why?
|
| Lentivirus | 1 | 2012 | 82 | 0.020 |
Why?
|
| Evidence-Based Practice | 1 | 2012 | 112 | 0.020 |
Why?
|
| Microglia | 1 | 2012 | 97 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 198 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 113 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 169 | 0.020 |
Why?
|
| Muscle Tonus | 1 | 1991 | 7 | 0.020 |
Why?
|
| Clonazepam | 1 | 1991 | 5 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2011 | 227 | 0.020 |
Why?
|
| Diazepam | 1 | 1991 | 21 | 0.020 |
Why?
|
| Species Specificity | 1 | 2011 | 549 | 0.020 |
Why?
|
| Body Height | 1 | 1992 | 215 | 0.020 |
Why?
|
| Cornea | 1 | 1996 | 654 | 0.020 |
Why?
|
| Aripiprazole | 1 | 2010 | 19 | 0.020 |
Why?
|
| Cerebellopontine Angle | 1 | 1990 | 7 | 0.020 |
Why?
|
| Information Theory | 1 | 2010 | 4 | 0.020 |
Why?
|
| Microinjections | 1 | 2010 | 52 | 0.020 |
Why?
|
| Doxycycline | 1 | 2011 | 117 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 484 | 0.020 |
Why?
|
| Beclin-1 | 1 | 2010 | 26 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 1993 | 310 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 503 | 0.020 |
Why?
|
| Injections, Intraocular | 1 | 2010 | 10 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2010 | 95 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2011 | 251 | 0.020 |
Why?
|
| Visual Perception | 1 | 2011 | 122 | 0.020 |
Why?
|
| Executive Function | 1 | 2011 | 110 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2003 | 1231 | 0.020 |
Why?
|
| Hemolysis | 1 | 2010 | 112 | 0.020 |
Why?
|
| Chelation Therapy | 1 | 2009 | 2 | 0.020 |
Why?
|
| 2,4-Dichlorophenoxyacetic Acid | 1 | 2009 | 2 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2012 | 420 | 0.020 |
Why?
|
| Ubiquitinated Proteins | 1 | 2009 | 3 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 1696 | 0.020 |
Why?
|
| Cytoprotection | 1 | 2009 | 38 | 0.020 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2009 | 11 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 457 | 0.020 |
Why?
|
| Glycosylation | 1 | 2010 | 120 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2010 | 210 | 0.020 |
Why?
|
| Pesticides | 1 | 2009 | 21 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2001 | 369 | 0.020 |
Why?
|
| Electron Transport Complex IV | 1 | 2009 | 38 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 341 | 0.020 |
Why?
|
| Solvents | 1 | 2009 | 43 | 0.020 |
Why?
|
| Equipment Safety | 1 | 2009 | 36 | 0.020 |
Why?
|
| History, Medieval | 1 | 2009 | 28 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 744 | 0.020 |
Why?
|
| Spain | 1 | 2009 | 59 | 0.020 |
Why?
|
| Microbiota | 1 | 2014 | 391 | 0.020 |
Why?
|
| Fingers | 1 | 1989 | 65 | 0.020 |
Why?
|
| Nerve Compression Syndromes | 1 | 1988 | 22 | 0.020 |
Why?
|
| Meningioma | 1 | 1990 | 121 | 0.020 |
Why?
|
| Ninhydrin | 1 | 2008 | 2 | 0.020 |
Why?
|
| Photophobia | 1 | 2008 | 9 | 0.020 |
Why?
|
| Sweat | 1 | 2008 | 7 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 483 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 284 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 830 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2009 | 143 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2010 | 171 | 0.020 |
Why?
|
| Fever | 1 | 2011 | 294 | 0.020 |
Why?
|
| PC12 Cells | 1 | 2008 | 25 | 0.020 |
Why?
|
| Meningeal Neoplasms | 1 | 1990 | 186 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2009 | 290 | 0.020 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2008 | 6 | 0.020 |
Why?
|
| Psychotic Disorders | 1 | 1990 | 135 | 0.020 |
Why?
|
| beta 2-Microglobulin | 1 | 2008 | 34 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2014 | 1002 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2011 | 270 | 0.020 |
Why?
|
| Catecholamines | 1 | 1988 | 58 | 0.020 |
Why?
|
| SSPE Virus | 1 | 1988 | 1 | 0.020 |
Why?
|
| Jaw | 1 | 1988 | 3 | 0.020 |
Why?
|
| Oculomotor Muscles | 1 | 2008 | 64 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2009 | 138 | 0.020 |
Why?
|
| Apolipoproteins | 1 | 2008 | 69 | 0.020 |
Why?
|
| Lithium | 1 | 1988 | 64 | 0.020 |
Why?
|
| Education | 1 | 2008 | 109 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2008 | 237 | 0.020 |
Why?
|
| Hydroxyquinolines | 1 | 2007 | 2 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2010 | 493 | 0.020 |
Why?
|
| Goats | 1 | 2007 | 55 | 0.020 |
Why?
|
| Sample Size | 1 | 2007 | 86 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1988 | 227 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2010 | 327 | 0.020 |
Why?
|
| Protein Folding | 1 | 2008 | 216 | 0.020 |
Why?
|
| Protein Precursors | 1 | 2008 | 153 | 0.020 |
Why?
|
| Mouth | 1 | 1988 | 61 | 0.020 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2008 | 115 | 0.020 |
Why?
|
| Cerebellar Neoplasms | 1 | 1990 | 285 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2008 | 208 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 1992 | 764 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2008 | 195 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 1615 | 0.020 |
Why?
|
| Antibodies, Antinuclear | 1 | 1987 | 28 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 1987 | 91 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2006 | 256 | 0.020 |
Why?
|
| Rabbits | 1 | 2007 | 708 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2006 | 313 | 0.020 |
Why?
|
| Peritoneovenous Shunt | 1 | 1986 | 5 | 0.020 |
Why?
|
| Cerebral Aqueduct | 1 | 1986 | 10 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2006 | 27 | 0.020 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2005 | 11 | 0.020 |
Why?
|
| Pyrrolidinones | 1 | 2005 | 17 | 0.020 |
Why?
|
| Body Mass Index | 1 | 1992 | 1556 | 0.020 |
Why?
|
| Peptide Elongation Factor 1 | 1 | 2005 | 9 | 0.020 |
Why?
|
| Metalloendopeptidases | 1 | 2006 | 101 | 0.020 |
Why?
|
| Peptide Elongation Factors | 1 | 2005 | 12 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2005 | 31 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2006 | 319 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2006 | 142 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2005 | 132 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 95 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2005 | 107 | 0.020 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2005 | 38 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2005 | 75 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 112 | 0.020 |
Why?
|
| Methamphetamine | 1 | 2005 | 32 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2006 | 382 | 0.020 |
Why?
|
| Child Development | 1 | 1988 | 267 | 0.020 |
Why?
|
| Caspases | 1 | 2005 | 162 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 254 | 0.010 |
Why?
|
| Antidepressive Agents | 1 | 2007 | 284 | 0.010 |
Why?
|
| Apolipoprotein E3 | 1 | 2004 | 5 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1987 | 418 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2005 | 622 | 0.010 |
Why?
|
| Glycoconjugates | 1 | 2004 | 7 | 0.010 |
Why?
|
| Weights and Measures | 1 | 2004 | 6 | 0.010 |
Why?
|
| Apolipoprotein E4 | 1 | 2004 | 45 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 890 | 0.010 |
Why?
|
| Biopsy | 1 | 1988 | 1239 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 2392 | 0.010 |
Why?
|
| NADPH Dehydrogenase | 1 | 2003 | 7 | 0.010 |
Why?
|
| Peroxynitrous Acid | 1 | 2003 | 7 | 0.010 |
Why?
|
| Indazoles | 1 | 2003 | 23 | 0.010 |
Why?
|
| Inflammation | 1 | 2011 | 1428 | 0.010 |
Why?
|
| RNA Interference | 1 | 2005 | 498 | 0.010 |
Why?
|
| COS Cells | 1 | 2004 | 275 | 0.010 |
Why?
|
| Voice Quality | 1 | 2003 | 19 | 0.010 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2005 | 276 | 0.010 |
Why?
|
| Electron Transport | 1 | 2003 | 53 | 0.010 |
Why?
|
| Mazindol | 1 | 2003 | 5 | 0.010 |
Why?
|
| Adrenergic Agonists | 1 | 2003 | 11 | 0.010 |
Why?
|
| Synaptosomes | 1 | 2003 | 31 | 0.010 |
Why?
|
| CHO Cells | 1 | 2003 | 160 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2002 | 60 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2005 | 426 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2004 | 575 | 0.010 |
Why?
|
| United Kingdom | 1 | 2003 | 189 | 0.010 |
Why?
|
| Tetanus Toxoid | 1 | 2002 | 45 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2003 | 291 | 0.010 |
Why?
|
| Cricetinae | 1 | 2003 | 413 | 0.010 |
Why?
|
| Gene Products, gag | 1 | 2002 | 19 | 0.010 |
Why?
|
| DNA Damage | 1 | 2005 | 513 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 1264 | 0.010 |
Why?
|
| Immunization, Secondary | 1 | 2002 | 103 | 0.010 |
Why?
|
| Ceruloplasmin | 1 | 2001 | 15 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 1388 | 0.010 |
Why?
|
| Genetic Carrier Screening | 1 | 2002 | 68 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2002 | 192 | 0.010 |
Why?
|
| Copper-transporting ATPases | 1 | 2001 | 24 | 0.010 |
Why?
|
| Copper | 1 | 2001 | 59 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2002 | 140 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2001 | 94 | 0.010 |
Why?
|
| Mass Screening | 1 | 2007 | 781 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2005 | 723 | 0.010 |
Why?
|
| China | 1 | 2001 | 243 | 0.010 |
Why?
|
| Immunization | 1 | 2002 | 307 | 0.010 |
Why?
|
| RNA, Transfer, Glu | 1 | 2000 | 2 | 0.010 |
Why?
|
| Receptors, Dopamine D4 | 1 | 2000 | 4 | 0.010 |
Why?
|
| Motor Skills Disorders | 1 | 2000 | 9 | 0.010 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2000 | 25 | 0.010 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 2000 | 10 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 1015 | 0.010 |
Why?
|
| Oxidopamine | 1 | 2000 | 15 | 0.010 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2003 | 309 | 0.010 |
Why?
|
| Choline O-Acetyltransferase | 1 | 1999 | 13 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2003 | 669 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 2000 | 112 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1999 | 175 | 0.010 |
Why?
|
| Greece | 1 | 1998 | 11 | 0.010 |
Why?
|
| Italy | 1 | 1998 | 97 | 0.010 |
Why?
|
| Nutrition Assessment | 1 | 2000 | 136 | 0.010 |
Why?
|
| Smell | 1 | 2000 | 120 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 2002 | 647 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 1999 | 201 | 0.010 |
Why?
|
| Cerebral Ventricles | 1 | 1998 | 80 | 0.010 |
Why?
|
| Writing | 1 | 1998 | 62 | 0.010 |
Why?
|
| Eating | 1 | 2000 | 374 | 0.010 |
Why?
|
| Paternity | 1 | 1996 | 8 | 0.010 |
Why?
|
| Forecasting | 1 | 1998 | 351 | 0.010 |
Why?
|
| Kinetics | 1 | 1999 | 1321 | 0.010 |
Why?
|
| Immunologic Memory | 1 | 1998 | 188 | 0.010 |
Why?
|
| Preoperative Care | 1 | 1998 | 354 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 1998 | 259 | 0.010 |
Why?
|
| Plasma Volume | 1 | 1994 | 15 | 0.010 |
Why?
|
| Glioma | 1 | 1999 | 488 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 1994 | 101 | 0.010 |
Why?
|
| DNA Probes | 1 | 1991 | 123 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1991 | 143 | 0.010 |
Why?
|
| Infusion Pumps | 1 | 1991 | 33 | 0.010 |
Why?
|
| Heart Rate | 1 | 1994 | 583 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 1991 | 119 | 0.010 |
Why?
|
| Karyotyping | 1 | 1991 | 328 | 0.010 |
Why?
|
| Interferon Type I | 1 | 1991 | 107 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1994 | 1352 | 0.000 |
Why?
|